GB2372991A - Flavivirus expression vector - Google Patents
Flavivirus expression vector Download PDFInfo
- Publication number
- GB2372991A GB2372991A GB0105877A GB0105877A GB2372991A GB 2372991 A GB2372991 A GB 2372991A GB 0105877 A GB0105877 A GB 0105877A GB 0105877 A GB0105877 A GB 0105877A GB 2372991 A GB2372991 A GB 2372991A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- flavivirus
- sequence
- protein
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710831 Flavivirus Species 0.000 title claims abstract description 112
- 239000013604 expression vector Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 104
- 229960005486 vaccine Drugs 0.000 claims abstract description 71
- 239000000427 antigen Substances 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 239000013598 vector Substances 0.000 claims abstract description 26
- 201000004792 malaria Diseases 0.000 claims abstract description 23
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 19
- 101710188315 Protein X Proteins 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000012678 infectious agent Substances 0.000 claims abstract description 5
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract 8
- 231100000676 disease causative agent Toxicity 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims description 313
- 208000003152 Yellow Fever Diseases 0.000 claims description 160
- 238000003780 insertion Methods 0.000 claims description 98
- 230000037431 insertion Effects 0.000 claims description 98
- 239000013612 plasmid Substances 0.000 claims description 86
- 101710204837 Envelope small membrane protein Proteins 0.000 claims description 76
- 101710145006 Lysis protein Proteins 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 33
- 241000710772 Yellow fever virus Species 0.000 claims description 30
- 229940051021 yellow-fever virus Drugs 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 24
- 208000001490 Dengue Diseases 0.000 claims description 22
- 206010012310 Dengue fever Diseases 0.000 claims description 22
- 208000025729 dengue disease Diseases 0.000 claims description 22
- 230000002238 attenuated effect Effects 0.000 claims description 21
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 20
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 19
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 19
- TWLQEIBUXHHZPI-UPPQRMANSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]p Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2[C@@H](CCC2)C(O)=O)CCC1 TWLQEIBUXHHZPI-UPPQRMANSA-N 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 12
- 108010004200 (asparaginyl-alanyl-asparaginyl-proline)3 Proteins 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 10
- 241000725619 Dengue virus Species 0.000 claims description 8
- 210000004779 membrane envelope Anatomy 0.000 claims description 7
- 208000024386 fungal infectious disease Diseases 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 238000002649 immunization Methods 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 description 69
- 235000018102 proteins Nutrition 0.000 description 65
- 239000002299 complementary DNA Substances 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 59
- 230000003612 virological effect Effects 0.000 description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 42
- 208000015181 infectious disease Diseases 0.000 description 42
- 210000003501 vero cell Anatomy 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 29
- 230000002458 infectious effect Effects 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 26
- 238000011161 development Methods 0.000 description 22
- 230000018109 developmental process Effects 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 230000002068 genetic effect Effects 0.000 description 20
- 230000005847 immunogenicity Effects 0.000 description 20
- 238000006386 neutralization reaction Methods 0.000 description 20
- 244000045947 parasite Species 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 19
- 239000000539 dimer Substances 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 230000010076 replication Effects 0.000 description 18
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 17
- 230000001681 protective effect Effects 0.000 description 17
- 238000001890 transfection Methods 0.000 description 16
- 230000004927 fusion Effects 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 239000000178 monomer Substances 0.000 description 14
- 239000004334 sorbic acid Substances 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- 241000991587 Enterovirus C Species 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 210000003046 sporozoite Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 101710144121 Non-structural protein 5 Proteins 0.000 description 10
- 240000007594 Oryza sativa Species 0.000 description 10
- 235000007164 Oryza sativa Nutrition 0.000 description 10
- 230000004075 alteration Effects 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 235000009566 rice Nutrition 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000001018 virulence Effects 0.000 description 8
- 241000223960 Plasmodium falciparum Species 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 210000000234 capsid Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 6
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000000521 hyperimmunizing effect Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000710815 Dengue virus 2 Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000009795 derivation Methods 0.000 description 5
- 206010014599 encephalitis Diseases 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013638 trimer Substances 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000709721 Hepatovirus A Species 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 101800001020 Non-structural protein 4A Proteins 0.000 description 4
- 241000224016 Plasmodium Species 0.000 description 4
- 241000223830 Plasmodium yoelii Species 0.000 description 4
- 230000010530 Virus Neutralization Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012297 crystallization seed Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000013636 protein dimer Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 101150013191 E gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101800001030 Non-structural protein 2A Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000710960 Sindbis virus Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 150000002333 glycines Chemical class 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 229940124735 malaria vaccine Drugs 0.000 description 3
- 210000003936 merozoite Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 241000701931 Canine parvovirus Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 241000710829 Dengue virus group Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000710803 Equine arteritis virus Species 0.000 description 2
- 101000726064 Escherichia coli (strain K12) Cold shock-like protein CspB Proteins 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 108700004715 Flavivirus NS1 Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 102100030385 Granzyme B Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 2
- 241000709727 Human poliovirus 3 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000710770 Langat virus Species 0.000 description 2
- 241000829333 Mesocricetus auratus polyomavirus 1 Species 0.000 description 2
- 241000711466 Murine hepatitis virus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 101800001019 Non-structural protein 4B Proteins 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 241000710764 Yellow fever virus 17D Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000005101 cell tropism Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000005156 neurotropism Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000006918 subunit interaction Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229960001515 yellow fever vaccine Drugs 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101710197318 Asparagine-rich protein Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150052200 CS gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000710844 Dengue virus 4 Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709744 Enterobacterio phage MS2 Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101800001632 Envelope protein E Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 108010075717 Flavivirus glycoprotein E Proteins 0.000 description 1
- 206010054261 Flavivirus infection Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000935008 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) dITP/XTP pyrophosphatase Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- -1 NS2B Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 101710195254 Non-structural glycoprotein Proteins 0.000 description 1
- 101710189818 Non-structural protein 2a Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 101000726057 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101800001127 Protein prM Proteins 0.000 description 1
- 101710165374 Putative helicase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 101710131114 Threonine-rich protein Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 241001529801 Tick-borne flavivirus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108700002693 Viral Replicase Complex Proteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004234 Yellow 2G Substances 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 229940124926 Yellow fever virus vaccine Drugs 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005173 gliding motility Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000037800 influenza D Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000006917 intersubunit interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- FEBNTWHYQKGEIQ-BIMULSAOSA-N nardin Natural products C[C@H]1CC[C@H](C=C(/C)C(=O)O)C2=C(C)CC[C@@H]12 FEBNTWHYQKGEIQ-BIMULSAOSA-N 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 235000008001 rakum palm Nutrition 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- FEBNTWHYQKGEIQ-UHFFFAOYSA-N valerenic acid Chemical compound CC1CCC(C=C(C)C(O)=O)C2=C(C)CCC12 FEBNTWHYQKGEIQ-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A Flavivirus vector for the expression of heterologous antigens comprising foreign gene sequences inserted at sites in the level of its envelope protein, wherein the sites are structurally apart from areas known to interfere with the overall flavivirus envelope protein structure. Also disclosed is a vaccine composition for immunisation against flavivirus and other infectious agents, specifically the causative agents of malaria.
Description
USE OF FLAVIVIRUS FOR THE EXPRESSION OF PROTEIN EPITOPES AND DEVELOPMENT OF NEW LIVE ATTENUATED VACCINE VIRUS TO IMMUNIZE AGAINST FLAVIVIRUS AND OTHER INFECTIOUS AGENTS
The present invention relates to a vaccine against infections caused by flavivirus.
More particularly to the use of the YF vaccine virus (17D) to express at the level of its envelope, protein epitopes from other pathogens which will elicit a specific immune response to the parental pathogen. There are provided new plasmids which were deposited on
December 21,2000 under the following accesion number with the American Type Culture Collection (ATCC), 10801 University Blvd. , Manassas, Va. 20110-2209: (i) pYFE200/13 accession number PTA-2854; (ii) pYF17D/8 accession number PTA-2855; (iii) pYFE200 accession number PTA-2856; (iv) pYFE200/8 accession number PTA-2857 and (v) pYFE200/1 accession number PTA-2858.
BACKGROUND OF THE INVENTION
Flaviviruses consists of 70 serologically cross-reactive, closely related human or veterinary pathogens causing many serious illnesses, which includes dengue fever, Japanese encephalitis (JE), tick-borne encephalitis (TBE) and yellow fever (YF). The Flaviviruses are spherical viruses with 40-60 run in diameter with an icosahedral capsid which contains a single positive-stranded RNA molecule.
YF virus is the prototype virus of the family of the Flaviviruses with a RNA genome of 10,862 nucleotides (nt), having a 5'CAP structure and a short 5'end nontranslated region (118 nt) and a nonpolyadenylated nontranslated 3'end (511 nt). The first complete nucleotide sequence of a flavivirus genome was determined on the genome of the YF 17D-204 vaccine strain virus by Rice et al (Rice C. M.; Lenches, E.; Eddy, S. R.; Shin, S. J. ; Sheets, R. L. and
Strauss, J. H. 1985."Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution". Science. 229: 726-733).
The single RNA is also the viral message and its translation in the infected cell results in the synthesis of a polyprotein precursor of 3,411 amino acids which is cleaved by proteolytic processing to generate 10 virus-specific polypeptides. From the 5'terminus, the order of the encoded proteins is: C; prM/M; E; NS1 ; NS2A; NS2B; NS3; NS4A; NS4B and
NS5. The first 3 proteins constitute the structural proteins, that is, form the virus together with the packaged RNA molecule and were named capsid (C, 12-14kDa), membrane (M, and its precursor prM, 18-22 kDa) and envelope (E, 52-54 kDa) all being encoded in the first quarter of the genome. The remainder of the genome codes for the nostructural proteins (NS) numbered in the order of synthesis from I through 5.
Three large nonstructural proteins have highly conserved sequences among flaviruses, NS1 (38-41 kDa), NS3 (68-70 kDa) and NS5 (100-103 kDa). A role in the replication of the negative strand RNA has been assigned to NS 1 (Muylaert IR, Chambers TJ, Galler R, Rice
CM 1996. Mutagenesis of N-linked glycosylation sites of YF virus NS 1 : effects on RNA accumulation and mouse neurovirulence. Virology 222, 159-168; Muylaert IR ; Galler R, Rice
CM 1997. Genetic analysis of Yellow Fever virus NS 1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J Virol71, 291-298;
Lindenbach BD, Rice CM 1999. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol. 73, 4611-4621 ; Lindenbach BD, Rice CM 1997. trans-complementation of yellow fever virus NS 1 reveals a role in early RNA replication. J Viral. 71, 9608-9617).
NS3 has been shown to be bifunctional with a protease activity needed for the processing of the polyprotein at sites the cellular proteases will not (Chambers TJ, Weir RC,
Grakoui A, McCourt DW, Bazan JF, Fletterick RJ, Rice CM 1990b. Evidence that the Nterminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl. Acad. Sci. USA 87, 8898-8902 ; Falgout B, Pethel M, Zhang YM, Lai CJ 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins.
J Virol65, 2467-2475; Yamshichikov VF, Compans RW 1995. Formation of the flavivirus envelope: role of the viral NS2B-NS3 protease. J. Virol. 69,1995-2003 ; Yamshichikov VF;
Trent, DW, Compans RW 1997. Upregulation of signalase processing and induction of prM
E secretion by the flavivirus NS2B-NS3 protease : roles of protease components. J Virol. 71, 4364-4371 ; Stocks CE, Lobigs M 1998. Signal peptidase cleavage at the flavivirus C-prM junction : dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide and prM. J Viral. 72,2141-2149). It also contains nucleotide triphosphatase/helicase activities (Gorbalenya AE, Koonin EV, Donchenko AP,
Blinov VM 1989. Two related superfamilies of putative helicases involved in replication, recombination repair and expression of DNA and RNA genomes. Nucl. Acids. Res. 17, 4713 4730; Wengler and Wengler, 1993) being therefore also associated with viral RNA replication. NS5, the largest and most conserved viral protein, contains several sequence motifs believed to be common to viral RNA polymerases (Chambers TJ, Hahn CS, Galler R,
CM Rice 1990a. Flavivirus genome organization, expression and evolution.
Ann. Rev. Microbiol. 44,649-688 ; O'Reilly EK, Kao CC 1998. Analysis of RNA-dependent
RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology 252,287-303) and exhibits RNAdependent RNA polymerase activity (Steffens S, Thiel HJ, Behrens SE 1999. The RNAdependent RNA polymerases of different members of the family Flaviviridae exhibit similar properties in vitro. J Gen. Virol. 80,2583-2590). Finally, a number of cis and trans acting elements in flavivirus RNA replication have been identified (Kromykh AA, Sedlak PL,
Westaway EG 2000. cis-and trans-acting elements in flavivirus RNA replication. J Virol. 74, 3253-3263).
The 4 small proteins NS2A, NS2B, NS4A and NS4B are poorly conserved in their amino acid sequences but not in their pattern of multiple hydrophobic stretches. NS2A has
been shown to be required for proper processing ofNSI (Falgout B, Channock R, Lai CJ 1989. Proper processing of dengue virus nonstructural glycoprotein NS 1 requires the Nterminal hydrophobic signal sequence and the downstream nonstructural protein NS2A.
J Viral. 63, 1852-1860) whereas NS2B has been shown to associate with NS3 to constitute the active viral protease complex (Chambers TJ, Nestorowicz A, Amberg SM, Rice CM 1993.
Mutagenesis of the yellow fever virus nonstructural polyportein: a catalitically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Viral. 65,67976807 ; Falgout B, Pethel M, Zhang YM, Lai CJ 1991. Both nonstructural proteins NS2B and
NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Viral 65,2467-2475 ; Jan LR Yang CS, Trent DW, Falgout B, Lai CJ 1995. Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases. J Gen. Viral. 76,573-580). NS4A has been suggested to interact with NSI integrating it into the cytoplasmic process of RNA replication (Lindenbach and Rice, 1999). Since viral RNA synthesis takes place in the cytosol in association with RER membranes it has been postulated
that these hydrophobic proteins would be embedded in membranes and through proteinprotein interactions participate in viral replication complexes together with NS3 and NS5 (Rice CM 1996. Flaviviridae: the viruses and their replication. In BN Fields, DM Knipe, PM
Howley (eds), Fields Virology 3rd ed, Raven Press, USA, p. 931-960).
Two strains of yellow fever virus (YF), isolated in 1927, gave rise to the vaccines to be used for human immunization. One, the Asibi strain, was isolated from a young african named Asibi by passage in Rhesus monkey (Macaca mulatta), and the other, the French
Viscerotropic Virus (FVV), from a patient in Senegal.
In 1935, the Asibi strain was adapted to growth in mouse embryonic tissue. After 17 passages, the virus, named 17D, was further cultivated until passage 58 in whole chicken embryonic tissue and thereafter, until passage 114, in denervated chicken embryonic tissue only. Theiler and Smith (Theiler M and Smith HH. 1937. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. JExp Med. 65,767-786) showed that, at this stage, there was a marked reduction in viral viscero and neurotropism when inoculated intracerebrally in monkeys. This virus was further subcultured until passages 227 and 229 and the resulting viruses, without human immune serum, were used to immunize 8 human volunteers with satisfactory results, as shown by the absence of adverse reactions and seroconversion to YF in 2 weeks (Theiler M, Smith HH 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med 65: 787-800).
In the late 1930's and early 1940's, mass vaccination was conducted in Brazil and various countries in Africa. Fox, J. P. et al (Fox, F. P. and Penna, H. A. (1943). Behavior of 17D yellow fever virus in Rhesus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am. J Hyg. 38: 52-172) described the preparation of the vaccine from 17D virus substrains. These substrains differed in their passage history and they overlapped with regard to time of their use for inocula and/or vaccine production. The substitution of each one by the next was according to the experience gained during vaccine production, quality control and human vaccination in which the appearance of symptomatology led to the discontinuation of a given strain.
As mentioned before, the YF virus Asibi strain was subcultured in embryonic mouse tissue and minced whole chicken embryo with or without nervous tissue. These passages yielded the parent 17D strain at passage level 180,17DD at passage 195, and the 17D-204 at
passage 204. 17DD was further subcultured until passage 241 and underwent 43 additional passages in embryonated chicken eggs until the vaccine batch used for 17DD virus purification (passage 284). The 17D-204 was further subcultured to produce Colombia 88 strain which, upon passage in embryonated chicken eggs, gave rise to different vaccine seed lots currently in use in France (I. Pasteur, at passage 235) and in the United States (Connaught, at passage 234). Each of these 17D-204 strains was plaque purified in different cell lines, the virus finally amplified in SW13 cells and used for cDNA cloning and sequence analyses. These 17D-204 are named C-204 (Rice, C. M.; Lenches, E.; Eddy, S. R.; Shin, S. J. ;
Sheets, R. L. and Strauss, J. H. (1985)."Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution". Science. 229: 726-733) and F-204 (Despres, P.; Cahour, A.; Dupuy, A.; Deubel, V.; Bouloy, M. ; Digoutte, J. P.; Girard, M.
(1987)."High genetic stability of the coding region for the structural proteins of yellow fever strain 17D". J. Gen. Virol. 68: 2245-2247), respectively. The 17D-213 strain was derived from 17D-204 when the primary seed lot (Sl 112-69) from the Federal Republic of Germany (FRG 83-66) was used by the World Health Organization (WHO) to produce an avian leukosis virus-free 17D seed (Sl 213/77) at passage 237.
The 17D-213 at passage 239 was tested for monkey neurovirulence (R. S.
Marchevsky, personal communication, see Duarte dos Santos et al. (Duarte dos Santos,
CN, Post, PR, Carvalho, R, Ferreira II, Rice CM and Galler, R. 1995. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus
Res. 35: 35-41) and was the subject of sequence analysis together with 17DD (at passage 284) and comparison to previously published nucleotide sequences of other YF virus strains (Duarte dos Santos et al, 1995; Asibi: Hahn, C. S.; Dalrymple, J. M.;
Strauss, J. H. and Rice, C. M. (1987)."Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it". Proc. Natl. Acad. Sci. USA.
84: 2029-2033; 17D-204 strain, C-204: Rice. C. M.; Lenches, E. M.; Eddy, S. R.; Shin,
S. J.; Sheets, R. L. and Strauss, J. H. (1985)."Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution". Science. 229: 726-733; F204: Despres, P.; Cahour, R.; Dupuy, A. ; Deubel, V.; Bouloy, M.; Digoutte, J. P. and
Girard, M. (1987)."High genetic stability of the coding region for the structural proteins of yellow fever virus strain 17D". J. Gen. Virol. 68: 2245-2247). Figure 1 depicts the
passage history of the original YF Asibi strain and derivation of YF 17D vaccine strains.
A total of 67 nucleotide differences, corresponding to 31 amino acid changes, were originally noted between the Asibi and 17D-204 genomic sequences (see Hahn,
C. S. et al, 1987). The comparison between the nucleotide sequences of 17DD and 17D213 substrains (see Duarte dos Santos et al, 1995) and the nucleotide sequence of 17D204 substrain (see Rice et al, 1985) showed that not all changes are common and thus not confirmed as being 17D-specific. Therefore, the 17D-substrain specific changes observed are very likely not related to attenuation but may reflect differences in behaviour of these strains in monkey neurovirulence tests. Therefore 48 nucleotide sequence changes are likely associated with YF virus attenuation. These are scattered along the genome, 26 are silent mutations and 22 led to amino acid substitutions.
The alterations noted in the E protein are important because it is the main target for humoral neutralizing response, i. e. , it is the protein where hemagglutination and neutralization epitopes are located, and it mediates cell receptor recognition and cell penetration, therefore targeting the virus to specific cells. Importantly, E protein accumulate the highest ratio of nonconservative to conservative amino acid changes.
Altogether, eleven nucleotide substitutions were observed in the E protein gene leading to 8 amino acid changes at positions 52,170, 173,200, 299, 305, 380 and 407 (respectively nucleotides 1127,1482, 1491,1572, 1870,1887, 1965 and 2112 from the RNA 5'end). Among these four are nonconservative changes and presumably would have a larger impact on protein structure and consequently function.
Alterations at amino acids 52 (G-+R) and 200 (KoT) are located at the base of domain II in the 3-D structure proposed for the E protein of Flaviviruses (Rey, F. A.;
Heinz F. X. ; Mandl, C. ; Kunz, C and Harrison, S. C. (1995)."The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution". Nature. 375: 291-298) which is conserved among Flaviviruses and contains cross-reactive epitopes as shown by Mandl,
C. W. et al (Mandl, M. W.; Guirakhoo, F.; Holzmann, H.; Heinz, F. X. and Kunz, C.
(1989)."Antigenic structure of the flavivirus envelope E protein at the molecular level using tick-borne encephalitis virus as a model". J. Virol. 63: 564-571). This domain II is highly crosslinked by disulphide bonds and undergoes low pH transition which is
related to exposing a strictly conserved and hydrophobic stretch of amino acids which are supposed to be involved in the fusion of the viral envelope to the endosome membrane.
Alterations at amino acids 170 and 173 in domain I of the E protein in the 3-D structure map very close to the position that a neutralization epitope was identified for tick-borne encephalitis (TBE) virus (see Mandl, C. W. et al, 1989). A mutation at position 171 of TBE virus E protein was shown to affect the threshold of fusionactivating conformational change of this protein and the 2 changes observed for YF 17D virus may be related to same phenomenon. It is conceivable that a slower rate of fusion may delay the kinetics of virus production and thereby lead to a milder infection of the host. Further evidence for the importance of this area comes from the work of Ryman et al (Ryman KD, Xie H, Ledger N, Campbell GA and Barrett ADT. 1997. Antigenic variants of yellow fever virus with altered neurovirulence phenotype in mice. Virology 230,376-380) showing that it encodes an epitope recognized by a wild-type-specific monoclonal antibody and reversion at this site may have contributed to added neurovirulence in the mouse model of a variant virus recovered from the 17D vaccine population.
Alterations at amino acids 299, 305, 380 and 407 are located in the domain III (see Rey, F. A. et al, 1995). This domain was suggested to be involved in viral attachment to a cellular receptor and consequently being a major determinant both of host range and cell tropism and of virulence/attenuation. The 4 amino acid changes reported for YF are located on the distal face of domain III. This area has a loop which is a tight turn in tick-borne encephalitis virus but contains 4 additional residues in all mosquito-borne strains. Because viruses replicate in their vectors, this loop is likely to be a host range determinant. This enlarged loop contains an Arginine-Glycine-Aspartic
Acid (Arg-Gly-Asp) sequence in all 3 YF 17D vaccine strains. This sequence motif is known to mediate a number of cell interactions including receptor binding and is absent not only in the parental virulent Asibi strain but also in other 22 strains of YF wild type virus (Lepiniec L, Dalgamo L, Huong VTQ, Monath TP, Digoutte JP and Deubel V.
(1994). Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic DNA fragments. J Gen. Virol. 75,417-423). Such a fact
suggests that the mutation from Threonine (Thr) to Arginine (Arg), creating a Arg-Gly
Asp motif, is likely to be relevant for the attenuated phenotype of the YF 17D strain.
Consistently, Lobigs et al (Lobigs M, Usha R, Nesterowicz A, Marschall ID, Weir RC and Dalgamo L. 1990. Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse neurovirulence.
Virology 176, 587-595) identified a Arg-Gly-Asp sequence motif (at amino acid 390) which led to the loss of virulence of Murray Valley encephalitis virus for mice. At least for YF, however, it is not the only determinant as shown by van der Most et al (van der
Most RG, Corver J, Strauss JH 1999. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology 265,83-95). It was suggested that the sequence in the RGD loop is critical for the conformation of E and minor changes in this region can have drastic effects on the stability of the protein. It is feasible, however, that such changes in structure and/or stability can affect the spectrum of cells infected by influencing the overall E protein structure and although that particular area would not be directly involved in the receptor binding. Since this loop is present in all mosquito bome flaviviruses and most of them carry a sequence that is very similar to the 17D
RGD motif it is conceivable that mutations in this region in other flaviviruses will affect viral fitness.
The importance of residue 305 was implied from the findings by Jennings et al (1994) who noted that the 17D virus recovered from a human case ofpostvaccinal encephalitis had a E-K change at position 303 and was found to have increased neurovirulence for both mice and monkeys.
It is noteworthy that the development of infectious cDNA for Japanese encephalitis (JE) virus made by Sumiyoshi, H. et al (Sumiyoshi H, Hoke CH and Trent
DW 1992. Infectious Japanese encephalitis virus RNA can be synthesized from in vitroligated cDNA templates. J Virol. 66: 5425-5431) allowed the identification of a mutation (Lys for Glu) at amino acid 136 of the E protein which resulted in the loss of neurovirulence for mice (see Sumiyoshi, H.; Tignor, G. H. and Shope, R. E. (1996).
"Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA". J. Infect. Dis. 171: 1144-1151). This means that domain I is an important area which contains a critical determinant of JE virus virulence in contrast
to most of the data obtained from the analyses of virulence for several other flaviviruses for which it is suggested that domain III would be the primary site for virulence/attenuation determinants.
For dengue type 2 virus Butrapet et al (2000) have suggested that attenuation determinants lie outside the structural area, namely, 5'UTR, NS 1 and NS3.
Little is known about the molecular basis of viscerotropism, i. e. the ability of wild type
YF virus to replicate and damage extraneural tissue, specially hepatic tissue, or the mutations responsible for the loss of this trait in the 17D virus. Further studies on 17D neurovirulence in the mouse model have suggested a complex genetic basis being most likely multigenic involving the structural and nonstructural proteins as well as the 3'end nontranslated region, the latter would presumably restrict replication. Nevertheless, such analyses of the E protein provides a framework for understanding several aspects of flavivirus biology and suggests that it should be possible to engineer viruses for the development of new live flavivirus vaccines.
Being the major component of the virion surface, the envelope protein E plays a dominant role in eliciting neutralizing antibodies and the induction of a protective response. This has been conclusively demonstrated by active immunization of animals with defined subviral components and recombinant proteins and by passive protection experiments with E protein-specific monoclonal antibodies. Linear epitopes have been mapped using synthetic peptides and are found in areas of the glycoprotein predicted to be hydrophilic, however, the induction of neutralizing antibodies seems to be strongly dependent on the native conformation of E. A number of neutralizing sites have been inferred from studies with monoclonal antibody scape mutants and have been mapped onto the 3D structure. Consistent with the suggested topology of the dimer on the virion surface most of these sites are located on the externally accessible upper side of the subunit. The scattered distribution of these neutralization escape mutations over the entire subunit indicates that antibody binding to any of the structural domains can lead to virus neutralization.
The neutralization epitopes recognized by monoclonal antibodies are conformational since E protein denaturation abolishes binding. Moreover, monoclonal antibodies will only react with synthetic peptides if they recognize an epitope which is present on the denatured E protein. Since the dimeric subunit forms part of a as yet undefined lattice on the virion surface, it is likely that certain epitopes are composed of elements from different subunits.
The mechanisms of neutralization by these antibodies remains speculative but relevant to the strategy of epitope insertion described below is the hypothesis that domain II may be involved in fusion of the viral envelope with the membrane of the endosome, which occurs under acidic pH. Fusion requires conformational changes that affect several neutralization epitopes, primarily within central domain I and domain II.
These changes are apparently associated with a reorganization of the subunit interactions on the virion surface, with trimer contacts being favored in the low pH form, in contrast to dimer contacts in the native form. Interference with these structural rearrangements by antibody binding represents one mechanism that may lead to virus neutralization (Monath and Heinz, 1996).
Low titer neutralizing activity and a significant degree of passive protection in mice has been observed by passive immunization with monoclonal antibodies against prM. This is due to a certain degree of partial cleavage of prM to form M by the furin in the Golgi system and thereby prM remains associated with the virus particle being an additional target for antibodies.
The NS 1 protein, also known as the complement fixing antigen elicits an antibody response during the course of flavivirus infection in man. It exists as cellassociated and secreted forms and it has been shown that immunization of animals with purified NS 1 or passive immunization of animals with monoclonal antibodies to it do elicit a protective immune response, the basis of which is still controversial.
The primary immunological role of nonstructural proteins, except for NS 1, seems to be targets for cytotoxic T cells. The specificity of T-cell responses to flaviviruses has been studied in human and mouse systems mainly with dengue and Japanese encephalitis
serocomplex viruses. In the course of dengue infection in man, both CD4+, CD8-as well as the opposite CD4-, CD8+ T-lymphocytes response have been detected and characterized. In bulk cultures of CD4+ lymphocytes as well as with CD4+ cell clones obtained from a single individual which had been infected with dengue, different
specific cross-reactivity patterns with several other flaviviruses is observed. Similar observations hold for CD8+ cells from infected humans and mice.
Antigenic determinants involved in cell mediated immunity have not yet been specifically localized in YF virus proteins as it has been for dengue and encephalitis virus such as MVE and JE. Such cytotoxic T cell determinants are found in all 3 structural and in the nonstructural proteins as well, specially in NS3. Some of these epitopes have been mapped to their primary sequence on the respective protein.
Livingston et al (Livingston PG, Kurane I, Lai CJ, Bray M, Ennis FA 1994.
Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8cytotoxic cell clones. J Viral. 68,3283-3288) reported the identification of several
HLA class II-restricted CD4+ CTL clones from a human donor capable of mediating specific lysis of virus-infected cells. It has been suggested that CD4+ CTL may be important mediators of viral clearance especially during reinfection with the same serotype of virus.
Vaccination of humans with recombinant poxviruses expressing the structural proteins prM and E of Japanese encephalitis elicited CD4-CD8+ CTLs directed to the
JE virus structural proteins although no specific epitopes were identified (Konish E,
Kurane I, Mason PW, Shope RE, Kanesa-Thasan N, Smucny JJ, Hoke CH, Ennis FA 1998. Induction of Japanese-encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 16,842-849).
More recently a JE virus E protein epitope recognized by JE-specific murine
CD8+ CTLs has been reported. The epitope was found to correspond to amino acids 60-68 of the JE virus protein which are located in domain II (Takada K, Masaki H,
Konishi E, Takahashi M, Kurane I 2000. Definition of an epitope on Japanese encephaltis virus envelope protein recognized by JEV-specific murine CD8+ cytotoxic
T lymphocites. Arch. Viral. 145,523-534). This epitope is located between strands a and b of domain II including two amino acid residues from each and the remaining of the epitope encompassing the intervening short loop. This area is exposed on the surface of the dimer.
Functional T-helper cell epitopes in the flavivirus E protein were identified by measuring B-cell response after immunization with synthetic peptides (Roehrig JT,
Johnson AJ, Hunt AR 1994. T-helper cell epitopes on the E glycoprotein of dengue 2 Jamaica virus. Virology 198, 31-38).
The capability to manipulate the genome of flaviviruses through infectious clone technology has opened new possibilities for vaccine development. This is so because virus can be recovered from complementary DNA by in vitro transcription and transfection of cultured cells with RNA, and these cDNAs corresponding to the complete viral genome allow introducing genetic modifications at any particular site of the viral genome. The pioneer study of Racaniello and Baltimore (Racaniello VR and
Baltimore D 1981. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 214,916-919) first showed the feasibility to regenerate virus from cloned cDNA. In the patent US 4,719, 177, Racaniello and Baltimore described, in details, the production of RNA viral cDNA by reverse transcribing viral RNA and inserting the resulting cDNA molecule into a recombinant DNA vector. The process was particularly concerned to the production of poliovirus double-stranded complementary DNA (ds cDNA). They found out that the transfected full-length poliovirus cDNA was itself infectious.
In addition, with the development of in vitro transcription systems (see Melton
DA, Krieg PA, Rabagliati MR, Maniatis T, Zinn K and Green MR 1984. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucal Acids. Res. 12,7035-7056), a much higher efficiency in synthesis of full length viral RNA, as compared to cDNA transcription in the cell, became possible. Furthermore, the development of improved transfection methodologies such as cationic liposomes and electroporation increased the efficiency of RNA transfection of cultured cells.
The construction and cloning of a stable full-length dengue cDNA copy in a strain of Escherichia coli using the pBR322 plasmid vector was described by Lai, C. J. et al (Lai CJ, Zhao B, Hori H and Bray M. 1991. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc. Natl. Acad. Sci. USA. 88, 5139-5143). They verified that RNA molecules produced by in vitro transcription of the full-length cloned DNA template were infectious, and progeny virus recovered from transfected cells was indistinguishable from the parental virus from which the cDNA
clone was derived. But, as mentioned in the Patent Application WO 93/06214, such an infectious DNA construct and RNA transcripts generated therefrom were pathogenic, and that the attenuated dengue viruses generated thus far were genetically unstable and had the potential to revert back to a pathogenic form overtime. To solve this problem, the Applicant proposed to construct cDNA sequences encoding the RNA transcripts to direct the production of chimeric dengue viruses incorporating mutations to recombinant DNA fragments generated therefrom. A preferred embodiment introduces deletions in the 3'end noncoding region (Men R, Bray M, Clark D, Chanock RM, Lai
CJ 1996. Dengue type 4 virus mutants containing deletions in the 3'noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Viral. 70,3930-3937 ; Lai CJ, Bray
M, Men R, Cahour A, Chen W, Kawano H, Tadano M, Hiramatsu K, Tokimatsu I,
Pletnev A, Arakai S, Shameen G, Rinaudo M 1998. Evaluation of molecular strategies to develop a live dengue vaccine. Clin. Diagn. Viral. 10: 173-179; Whitehead SS, Men
RH Lai CJ, Murphy BR, Reynolds MJ, Perreault J, Karron RA, Durbin AP, 2000. A live attenuated dengue virus type 4 vaccine candidate with a 30-nucleotide deletion in the 3'end UTR is attenuated and immunogenic in humans. 19th Annual Meeting,
American Society for Virology, pp. 125).
The construction of full-length YF 17D cDNA template that can be transcribed in vitro to yield infectious YF virus RNA was first described by Rice et al (Rice CM,
Grakoui A, Galler R and Chambers T 1989. Transcription of infectious yellow fever
RNA from full-length cDNA templates produced by in vitro ligation. The New Biologist 1: 285-296). Because of the instability of full-length YF cDNA clones and their toxic effects on Escherichia coli, they developed a strategy in which full-length templates for transcription were constructed by in vitro ligation of appropriate restriction fragments.
Moreover, they found that the YF virus recovered from cDNA was indistinguishable from the parental virus by several criteria. The YF infectious cDNA is derived from the 17D-204 substrain. Notwithstanding the YF virus generated from this YF infectious cDNA is rather attenuated, it cannot be used for human vaccination because of its residual neurovirulence, as determined by Marchevsky, R. S. et al (Marchevsky RS,
Mariano J, Ferreira VS, Almeida E, Cerqueira MJ, Carvalho R, Pissumo JW, Travassos
da Rosa APA, Simoes MC, Santos CND, Ferreira II, Muylaert IR, Mann GF, Rice CM and Galler R 1995. Phenotypic analysis of yellow fever virus derived from complementary DNA. Am. J. Trop. Med Hyg. 52, 75-80). Although these results showed the virus was not ideally attenuated for YF 17D vaccine it was the first demonstration for a flavivirus that it was possible to develop from a few micrograms of
DNA template a whole seed lot under Good Manufacturing Practices (GMP) using current methodology for the production of YF vaccine.
Galler and Freire (US patent application 09/058411) have approached the recovery of fully attenuated virus from YF cDNA by engineering a number of mutations into the original 17D-204 cDNA (Rice et al, 1989) based on the sequence of the 17DD substrain (Duarte dos Santos et al, 1995). This substrain has been used in Brazil for YF vaccine production since the late 1930's with excellent records of efficacy and safety.
Here, virus was recovered from the genetically-modified cDNA template through the transfection of certified CEF cells under GMP (US patent application 09/423517).
Altogether 3 transfection lots were derived which gave rise to two primary and three secondary seed lots by further passaging in CEF cells with all the relevant quality controls for human vaccine production using this cell system. Average titer of formulated virus was 6. 71oglOPFU/ml. Analysis of viral genetic stability was carried out by serial passaging in CEF cultures and studying several parameters such as plaque size, mouse neurovirulence and nucleotide sequence determination with satisfactory results.
Further nucleotide sequencing results on the chimeric 17D204/DD virus was obtained after viral reisolation from viremic monkey sera. There were no genomic changes (Galler R, Freire MS and JaborAV, unpublished). But YF 17D virus exists today as two main substrains used for vaccine production world wide, namely 17D-204 and 17DD, and differences in their sequences have been noted (Galler R, Post PR,
Duarte dos Santos CN and Ferreira II. 1998. Genetic variability among yellow fever virus 17D substrains. Vaccine 16, 1024-1028). espite the overall genetic stability of YF 17D virus a major concern is the genetic stability of the foreign epitope since the virus does not need it and in fact its replication has been somewhat restricted. Although viral genetic variability is
minimized by the use of seed lot system, to produce production-sized seeds at least 4 passages are necessary starting out from cDNA (US 6, 171, 854).
The first aspect that has to be considered when using a given flavivirus cDNA backbone for the expression of heterologous proteins is whether one can indeed recover virus with the same phenotypic markers as originally present in the virus population that gave rise to the cDNA library. That is extremely applicable to YF 17D virus given the well known safety and efficacy of YF 17D vaccine.
In fact different technical approaches to constructing recombinant viruses based on a flavivirus, in particular YF 17D virus, are possible and will vary according to the region of the genome selected for insertion and to the antigen to be expressed. One major approach has been the creation of chimeric viruses through the exchange of prM/M/E genes as first established for DEN-4 virus chimeras (Lai et al, 1998, US 5,494, 671). The prM/M/E genes of dengue virus serotypes 1,2 and 3 were inserted into the dengue 4 infectious clone resulting in chimeric virus with reduced virulence for mice and monkeys (Lai et al, 1998) This allows the removal of the major immunogens of the vector thereby reducing the criticism on previous immunity.
The same type of construction was made for tick-borne encephalitis (TBE) and
Langat viruses (Pletnev AG, Bray M, Huggins J, Lai CJ 1992. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl.
Acad. Sci. USA. 89: 10532-10536; Pletnev AG, Men R. 1998. Attenuation of Langat virus tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type
4. Proc. AM. Acad. Sci. USA. 95 : 1746-1751) resulting in virus attenuated for mice.
Chambers et al (Chambers TJ, Nestorowicz A, Mason PW, Rice CM 1999.
Yellow fever/Japanese encefalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095-3101) have described the first chimeric virus developed with the YF 17D cDNA from Rice et al (1989) by the exchange of the prM/M/E genes with cDNA derived from JE SA14-14-2 and Nakayama strains of JE virus. The former corresponds to the live attenuated vaccine strain in use nowadays in China.
Guirakhoo et al (Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J.
Barrett ADT, Monath TP 1999. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus
(Chimerivax-JE) as a live, attenuated vaccine candidate against fever Japanese encephalitis. Virology 257 : 363-372) Monath et al (Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett ADT, Shope RE, Rattterree M,
Chambers TJ, Guirakhoo F 1999. Recombinant, chimeric live, attenuated vaccine (Chimerivax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in nonhuman primates. Vaccine 17: 1869-1882) and
W098/37911 have brought it closer to vaccine development. Here, chimeric virus was recovered after transfection of certified FRhL cells with 5 additional passages of the virus to produce seed lots and experimental vaccine lot (5th passage) all under GMP in certified cells. Virus yields in this cell system were not provided.
Chimeric virus retained nucleotide/amino acid sequences present in the original
SA14-14-2 strain. This vaccine strain differs, in prM/M/E region, from the parental virus in 6 positions (E-107; E138; E176 : E279; E315; E439). Mutations are stable across multiple passages in cell culture (Vero) and mouse brain but not in FRhL cells.
Despite previous data on the genetic stability of such virus, one of the 4 changes in the
E protein related to viral attenuation had reverted during the passaging to produce the secondary seed.
In a dose-response study neutralizing antibodies specific for prM/M/E were elicited in all groups of monkeys with different doses even with as little as 100 PFUs
and conferred full protection against IC challenge with wild type JE. However, the lower the chimeric virus dose the more residual histopathological changes were noted in the SNC after IC challenge with wild type JE virus.
The first chimeric 17D/dengue virus developed (Guirakhoo F, Weltzin R,
Chambers TJ, Zhang ZX, Soike K, Rattterree M, Arroyo J, Georgakopoulos K, Catalan
J, Monath TP 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. ViroL 74,5477-5485) involved prM/M/E gene replacement (fusion at the signalase cleavage site) with a den2 cDNA.
All virus regeneration and passaging was done in Vero PM cells (a cell bank from
Pasteur-Merieux) allegedly certified for live vaccine virus production. Recombinant virus retained the original den2 prM/M/E sequences even after 18 serial passages in
Vero cells but some variation was noted in YF genes. Phenotypic analysis of chimeric 17D/den2 virus showed it does not kill mice even at high doses (6. 0 loglO PFU) in contrast to YF 17D which kills nearly 100% at 3.0 loglOPFU. Antibody response and full protection was elicited by the 17D-DEN2 chimera in both YF immune and flavivirus-naive monkeys. In a dose response study even at the lowest dose (2.0 log I OPFU) chimeric virus replicated sufficiently to induce a protective neutralizing antibody response as no viremia was detected in these animals after challenge with a wild type dengue 2 virus.
Although YF 17D virus is known to be more genetically stable than other vaccine viruses, such as poliovirus, given the extremely low number of reports on adverse events following vaccination, a few mutations have been detected occasionally when virus derived from humans were sequenced (Xie H, Cass AR, Barrett ADT 1998.
Yellow fever 17D vaccine virus isolated from healthy vaccines accumulates few mutations. Virus Research 55: 93-99). Guirakhoo et al have reported a few changes in the YF moiety of chimeric 17D/dengue 2 virus which had been passaged up to 18 times in cell culture.
Galler et al (in preparation) have also developed a similar chimeric 17D-DEN-2 virus. However, the 17D backbone was genetically modified (US 6,171, 854). These viruses were characterized at the genomic level by RT/PCR with YF/Den-specific primers and nucleotide sequencing over fusion areas and the whole DEN2-moieties.
The polyprotein expression/processing was monitored by SDS-PAGE analysis of radiolabeled viral proteins immunoprecipitated with specific antisera, including monoclonal antibodies. Recognition of YF and DEN-2 proteins by hiperimmune antisera, and monoclonal antibodies was also accomplished by viral neutralization in
plaque formation reduction tests and indirect immunofluorescence on infected cells.
The growth of recombinant viruses was examined in several cell substrates such as
Vero, LLC-MK2, C6/36, MRC5, and CEF. Only YF virus grew in all of them to high titers but the chimeric viruses failed to replicate in the vaccine-production certified cells (CEF and MRC5) similarly to DEN-2 virus. Analysis of viral virulence was performed by intracerebral inoculation of mice (103 PFU) and the chimeric viruses turned out to be more attenuated in this system than the YF 17D virus. With regard to the
immunogenicity, studies in the mouse model indicate the chimeric virus does induce a protective response against an otherwise lethal dose of mouse neurovirulent DEN-2 New Guinea C virus.
One alternative to develop YFV 17D as a vector for heterologous antigens is the expression of particular epitopes in certain regions of the genome. The feasibility of this approach was first demonstrated for poliovirus (reviewed in Rose CSP, Evans DJ 1990 Poliovirus antigen chimeras. Trends Biotechnol. 9: 415-421). The solution of the three-dimensional structure of poliovirus allowed the mapping of type-specific neutralization epitopes on defined surface regions of the viral particle (Hogle JM, Chow
M & Filman DJ (1985). Three-dimensional structure of poliovirus at 2.9 resolution.
Science 229: 1358-1365). One of the surface loops of the VP1 protein was used for the insertion of type 3 epitope which was recognized by primate antisera to poliovirus type 3 showing that the chimera was not only viable but also that the inserted epitope was presented with the same conformation as in the surface of the type 3 virus (Murray MG,
Kuhn RJ, Arita M, Kawamura N, Nomoto A & Wimmer E (1988) Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc. NatLAcad. Sci. USA 85 : 3203-3207). However, to argue strongly against it is the observation that the same site was used for the insertion of different epitopes of hepatitis A virus but the immunogenicity of the inserted peptides was very poor (Lemon SM, Barclay W, Ferguson M, Murphy P, Jing
L, Burke K, Wood D, Katrak K, Sangar D, Minor PD & Almond JW (1992).
Immunogenicity and antigenicity of chimeric picomaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV. Virology 188 : 285-295).
Influenza viruses are also well studied from the structural view and 3D structures are available for both hemagglutin and neuraminidase viral proteins. Li et al (Li S, Polonis V, Isobe H, Zaghouani H, Guinea R, Moran T, Bona C, Palese P 1993.
Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Viral. 67: 6659-6666) have described insertion of HIV epitope into a loop of antigenic site B of influenza virus and the generation of specific B and T cell responses to the epitope.
London et al (London SD, Schmale oh AL, Dalrymple JM & Rice CM (1992) Infectious enveloped RNA virus antigenic chimeras. Proc. Natl. Aca. Sci. USA 89 : 207 211) developed chimeric Sindbis virus expressing a single well-defined neutralizing epitope of Rift Valley fever virus inserted by random mutagenesis. Insertion sites, permissive for recovery of viruses with growth properties similar to the parental virus, were found in one of the virion glycoproteins. For these chimeras the epitope was expressed at the virion surface and stimulated a partially protective immune response to
RFV infection of mice.
De Vries et al (de Vries AAF, Glaser AL, Raasman MJB, de Haan CAM, Samataro GJG, Rottier PJM 2000. Genetic manipulation of equine arteritis virus using full-length cDNA clones: separation of overlapping genes and expression of a foreign epitope. Virology 270,84-97) have engineered equine arteritis virus, also a positivestranded RNA virus with a genome similar in size to YF 17D but with different replication strategy. Insertion of a nonapeptide epitope recognized by an MHV-specific monoclonal antibody with a functional 0-glycosylation site resulted in recombinant virus expressing both properties of the epitope. However, growth of the virus was clearly reduced as compared to the parental virus although 3 serial passages did not result in the loss of the insert.
Bendahmane et al (Bendahmane M, Koo M, Karrer E, Beachy RN 1999. Display of epitopes on the suface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions. J Mol. Biol. 290,9-20) have described the creation of chimeric tobacco mosaic virus expressing defined epitopes of rabies and murine hepatitis virus. The foreign epitopes were expressed on the carboxi terminus of the viral coat protein, the stucture and biophysical properties of which is well established. Although both insertions gave rise to viable viruses the generation of lesions in plants infected by either virus differed. It was observed that the isoelectric point (PI) of the epitope affected the overall hybrid coat protein pI/charge and that was important for successful epitope display. It was also noted the lack of tolerance to positively charged epitopes on the surface ofTMV.
A number of other studies employing virus-like particles to express defined foreign protein epitopes have been described as they seem to be able to potentiate the
immunogenicity of foreign epitopes presented on their surface. Heal et al (Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW 2000. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine 18,251-258) have used the coat protein of bacteriophage MS2 to express foregin epitopes based on a ss-hairpin loop at the N-terminus of this protein which forms the most radially distinct feature of the mature capsid. A chimeric capsid expressing a Plasmodium liver-stage antigen epitope (LSA-1) stimulated in mice a polarized Th-1 response similar to the human response to this antigen in nature.
Of interest is also the study by Sedlik et al (Sedlik C, Sarraseca J, Rueda P,
Leclerc C, Casal JI 1995. Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. J. Gen. Viral. 76,2361-2368). They have inserted poliovirus T and B cell epitopes into the single-stranded DNA genome of canine parvovirus. Insertions were made at the N terminus of the viral VP2 on the particle structure. There was no antibody response to the epitope whereas a T cell response could be observed in vitro for the expressed T cell epitope. That suggested the
N-terminus is not an adequate site for the expression of humoral epitopes. Rueda et al (Rueda P, Hurtado A, Barrio M, Torrecuadrada JLM, Kamstup S, Leclerc C, Casal JI 1999. Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles. Virology 263,8999) have extended these studies with canine parvovirus and inserted a poliovirus humoral epitope into the 4 loops of the viral VP2 carboxi terminus on the particle structure. Only loop 2 allowed the generation of antibodies to the epitope but not poliovirus neutralizing antibodies. That was accomplished by inserting the epitope at adjacent amino acids suggesting that minor displacements at the insertion site cause dramatic changes in the accessibility of the epitope and the induction of antibody responses.
Chimeric hepatitis B virus core particles carrying hantavirus epitopes have been described by Ulrich et al (Ulrich R, Koletzki D, Lachman S, Lundkvist A, Zankl A,
Kazaks A, Kurth A, Gelderblom HR, Borisova G, Meisel H, Krueger DH 1999. New chimaeric hepatitis B virus core partciles carrying hantavirus (serotype Puumala)
epitopes : immunogenicity and protection against virus challenge. J Biotechnol. 73, 141153). Insertion of as much as 45 and 114 amino acids ofhantavirus capsid protein resulted in protection of natural hosts to the virus.
The formation of chimeric virus-like partciles with hamster polyoma virus major capsied protein has been describe by Gedvilaite et al (Gedvilaite A, Froemmel C,
Sasnaukas K, Micheel B, Oezel M, Behrsing 0, Stanilius J, Jandrig B, Schemeck S,
Ulrich R 2000. Formation of immunogenic virus-like particles by inserting epitopes into surfac-exposed regions of hamster polyomavirus major capsid protein. Virology 273,21-35). They have predicted from the 3D-structure 3 areas that would be surface exposed and expression of a 5-amino acid hepatitis B virus capsid epitope resulted in the recognition by a monoclonal antibody to the epitope.
For Flaviviruses, neutralizing epitopes to other viral agents could be inserted in regions of the viral envelope where one detects genetic variability by nucleotide sequencing. Such an approach was first tested after changing 2 amino acids in the envelope protein gene of the YF infectious cDNA by the corresponding amino acid sequence of Murray Valley encephalitis virus (MVE) which was previously characterized by monoclonal antibody as a neutralizing MVE epitope The chimera, however, was not viable suggesting that particular area of the E protein (amino acids 192-193 from the amino terminal) is critical for YF virus viability (R. Weir and C. Rice, pers. commun.).
In short, to obtain a Flavivirus-based vaccine virus expressing foreign antigens for the development of new live vaccines using recombinant DNA techniques, it is necessary, cumulatively: (1) to design strategies that allow the introduction of foreign antigens without compromising the structure and function of the virus; (2) to assure that the infectious cDNA construct and RNA transcripts generated therefrom give rise to virus which is not pathogenic, does not have the potential to revert to a pathogenic form; and that the foreign antigen sequence is genetically stable once integrated into the viral genome;
(3) the Flavivirus generated from cloned cDNA, in addition to being attenuated should retain its immunological properties and present the expressed foreign antigen such that it elicits the appropriate immune response.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a safe and effective Flavivirus vaccine virus obtained from a cloned cDNA having phenotypic characteristics such as attenuation and immunogenicity, and which should also stably express and elicit an immune response to foreign antigens.
In one embodiment, the present invention relates to a method for the production of Flavivirus as a vector for heterologous antigens comprising the introduction and expression of foreign gene sequences into an insertion site at the level of the envelope protein of any Flavivirus, wherein the sites are structurally apart from areas known to interfere with the overall flavivirus E protein structure and comprising: sites that lie on the external surface of the virus providing accessibility to antibody; not disrupt or significantly destabilize the three-dimensional structure of the E protein and not interfere with the formation of the E protein network within the viral envelope.
In another embodiment the present invention is related to a strategy that allows introducing foreign gene sequences into the loop of the envelope protein of YF 17D virus and other flaviviruses.
Another embodiment of the present invention relates to a new version of YF infectious cDNA template that is 17DD-like and which resulted of insertion of malarial gene sequences.
In another embodiment of the present invention, there is provided new YF plasmids which have the complete sequence of the YF infectious cDNA and malarial gene sequences.
Another embodiment of the present invention are Flavivirus as a vector for heterologous antigens wherein the Flavivirus is obtainable according to the method herein described.
In another embodiments there is provided recombinant YF viruses which are regenerated from a YF infectious cDNA and express different malarial epitopes.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 illustrates the passage history of the original YF Asibi strain and derivation of YF 17D vaccine strains.
FIGURE 2 shows the sequence alignment of the soluble portions of the Envelope proteins from tick-borne encephalitis virus (tbe), yellow fever virus (yf), japanese encephalitis virus (je) and Dengue virus type 2 (den2).
FIGURE 3: shows a schematic representation of the CS protein of Plasmodium sep..
FIGURE 4: displays the structure of the plasmid pYF17D/14.
FIGURE 5: shows the structure of the plasmid pYFE200.
FIGURE 6: shows the sequence alignment between tbe and yf, but with the introduction of an insertion sequence (highlighted in bold and underlined) between residues 199 and 200 of yf, located in the loop between p-strands f and g. As in figure 2, the alignment shown is that used for model building of the modified yf E protein and deliberate misalignments are shown shaded. Elements of secondary structure are shown as horizontal bars between the two sequences.
FIGURE 7: sets forth two views of the modelled yfE protein including the
SYVPSAEQI insertion sequence within the fg loop. The domains are coloured individually, domain I (red), domain II (yellow) and domain III (blue). In the upper panel the E protein dimer is seen perpendicular to the viral membrane and in the lower panel is viewed within the membrane plane, perpendicular to the long axis of the dimer.
The insertion site (in cyan) lies close to the proximal interface between the two constituent monomers of the dimer and can be seen to be partially buried.
FIGURE 8: sets forth the superposition often models of the YF E protein including the insertion sequence GG (NANP) 3GG within the fg loop. In each model the insertion sequence is shown in a different color while the remainder of the structure is shown in green. The great diversity in conformations for the loop, while essentially
preserving the rest of the structure, indicates that the large volume of space available to the insertion peptide.
FIGURE 9: shows the molecular surface of the YF E protein dimer for one of the ten models of Figure 8. In the upper panel, the blue and red dots indicated on each monomer, represent the entrance and exit to the insertion peptide. In the middle panel the two-residue N- (blue) and C-terminal (red) glycine spacers are shown, indicating their role in lifting the (NANP) 3 sequence above the molecular surface. In the lower panel the (NANP) 3 insertion is shown in green.
FIGURE 10: sets forth an indirect immunofluorescence assay using a monoclonal antibody directed to (NANP) 3 repeat.
FIGURE 11: displays a SDS-PAGE gel of the 17D/8 virus obtained by immunoprecipitation of metabolic labeled viral proteins.
FIGURE 12: illustrates the comparative plaque size analysis among YF 17D/8 virus, YF17D/14 and YF17D/Gl/2-derived virus.
FIGURE 13: shows viral growth curves in CEF (15a) and VERO cells (15b).
FIGURE 14: sets forth the size of virus plaques formed on Vero cell monolayers after serial propagation of the viruses in Vero and CEF cell cultures.
FIGURE 15: shows the comparative growth curves of the different recombinant viruses in Vero cells.
FIGURE 16: shows the plaque size analysis of the different recombinant YF viruses.
DETAILED DESCRIPTION OF THE INVENTION
For many diseases, the ideal vaccine is a live attenuated derivative of the pathogen, which induces strong, long-lasting protective immmune responses to a variety of antigens on the pathogen without causing illness. Development of such vaccine is often precluded by difficulties in propagating the pathogen, in attenuating it without loosing immunogenicity and ensuring the stability of the attenuated phenotype. One alternative is the use of known attenuated microorganisms for the expression of any antigen of interest.
The ability to genetically engineer animal viruses has changed the understanding of how these viruses replicate and allowed the construction of vectors to direct the expression of heterologous proteins in different systems. DNA viruses such as SV40,
Vaccinia, adenoviruses and herpes have been used as vectors for a number of proteins.
More recently RNA viruses, both positive and negative stranded, (Palese P 1998. RNA virus vectors: where are we and where do we need to go? Proc. Natl. Acad Sci. USA 95, 12750-2) have also become amenable to genetic manipulation and are preferred vectors as they lack a DNA phase ruling out integration of foreign sequences into chromosomal DNA and do not appear to downmodulate the immune response as large
DNA viruses do (eg. vaccinia and herpes).
Flaviviruses have several characteristics which are desirable for vaccines in general and that has attracted the interest of several laboratories in developing it further to be used as a vector for heterologous antigens. Particularly for YF17D virus, these characteristics include well-defined and efficient production methodology, strict quality control including monkey neurovirulence testing, long lasting immunity, cheapness, single dosis, estimated use is over 200 million doses with excellent records of safety (only 21 cases of post-vaccinal encephalitis after seed lot system implementation in 1945 with an incidence in very young infants (9 months) of 0. 5-4/1000 and > 9 months at 1/8 million).
The fact that the 3-D structure for the flavivirus E protein is available (Rey et al, 1995) would support the approach first used for poliovirus by examining the 3Dstructure and selecting sites for insertion which are less likely to interfere with the overall E protein structure. The major concern about inserting epitopes into flaviviruses
E protein, in particular into the YF 17D E protein, relates to the fact that this protein is the main target for humoral neutralizing response, it is the protein where hemagglutination and neutralization epitopes are, and it is the protein that mediates cell receptor recogniton and cell penetration, therefore targeting the virus to specific cells.
By inserting a new epitope somewhere in the E protein of a given flavivirus one or more of these properties could be changed unless the analysis of the 3D structure allows the identification of potential insertion sites structurally apart from areas known to mediate one or more of these processes.
Regarding the Tick-borne encephalitis virus E protein, two distinct crystal forms of its soluble fragment were obtained by Rey et al. (Rey et al., 1995). In both, the E protein shows a similar dimeric arrangement in which two monomers are related by a molecular twofold axis which is crystallographic in one crystal form and noncrystallographic in the other. The repeated appearance of the same dimer in both cases suggests that this is not an artifact of crystallization but represents the true oligomeric arrangement of the E protein as inserted into the viral envelope at neutral pH. The dimer presents an elongated flattened structure with overall dimensions of approximately 150 x 55 x 30 A. Its shortest dimension lies perpendicular to the viral membrane and the whole structure presents a mild curvature yielding an external surface which is somewhat greater than the corresponding internal surface. This curvature may aid in the closure of the spherical viral particle.
Each monomer is composed of three domains; domain I (the central domain), domain Il (the dimerization domain) and domain III (the immunoglobulin-like receptor binding
domain), all of which are dominated by-sheet secondary structure. Domain I is discontinuous, being composed of three separate segments of the polypeptide chain, and is dominated by an up-and-down eight-stranded p-barrel of complex topology. Domain II is responsible for the principal interface between the two monomers proximal to the two-fold axis and is formed by the two segments of the polypeptide chain which divide domain 1. It is an elongated domain, heavily crosslinked by disulphide bridges and composed principally of two structural components; 1) a five-stranded anti-parallel - sheet onto one side of which pack the only two a-helices of the structure and 2) asz sandwich made up of a three-stranded p-sheet packed against a -hairpin. This sandwich sub-domain includes the fusion peptide believed to be important for the fusogenic activity of the virus. It nestles into a cavity formed by the interdomain contacts between domains I and III of the opposite monomer and therefore forms part of a second interface region between the two monomers which lies more distal to the twofold axis to that mentioned above. Domain III is continuous and presents a somewhat modified C-type immunoglobulin (Ig) fold. Using the conventional nomenclature for such folds (Bork P, Holm L, Sander C, 1994 The immunoglobulin fold, J Mol. Biol. 242,309-320), the C, F and G strands of this domain face outwards
from the monomer and represent a region critical in the determination of host range and cell tropism and is probably therefore fundamental for cell attachment. The opposite face of the Ig-like domain forms the interface with domain I, and together with regions from the p-sandwich sub-domain of the opposite monomer, is important in forming the dimer interface distal to the twofold axis. This interface is further protected by the carbohydrate moiety present on domain 1.
The-strands from domain I are named Ao to Io, those from domain II named a to I and those from domain III named A to G, in all cases labeled consecutively from the
N-terminus (in domain III a distortion of the typical C-type Ig-fold leads to the creation of additional strands Ax, Cx and Dx). With the exception of the two short a-helices of domain II, all connections between the -strands of a given domain as well as the linkers which lead from one domain to another are either -turns or loops which vary greatly in length. In general terms all such loops are either buried within the structure (inaccessible to solvent) or exposed on one or more of the internal, external and lateral surfaces of the dimer.
On exposure to low pH the network of E protein dimers on the viral surface must rearrange into trimers. This must envolve large alterations to the monomermonomer contacts and possibly also to the relative domain orientations within a given subunit, if not to internal reorganization of the tertiary structure of the domains themselves. In participating in both proximal and distal contacts, domain II is likely to suffer the greatest changes, consistent with the fact that the binding of monoclonal antibodies to this domain is strongly affected by the dimer to trimer transition (Heinz
FX, Stiasny K, Puschnerauer G, Holzmann H, Allison SL, Mandl CW, Kunz C 1994
Structural-Changes And Functional Control Of The Tick-Borne Encephalitis-Virus
Glycoprotein-E By The Heterodimeric Association With Protein prM Virology 198, 109-117).
For the design of insertions of epitopic peptides into the E protein of a given
Flavivirus and the subsequent evaluation of their viability the inventors of the present invention developed the following strategy. Initially it was necessary to produce a three-dimensional model for the E protein of a selected Flavivirus. The sequence of the yellow fever 17DD strain was used for this purpose and its alignment with that of tick
borne encephalitis (tbe) virus was generated initially with the program MULTALIGN (Barton GJ, Stemberg MJE, 1987, A Strategy For The Rapid Multiple Alignment Of Protein Sequences-Confidence Levels From Tertiary Structure Comparisons J Mol Viol 198, 327-337) and subsequently with reference to the 3D structure of the latter, such that all insertions and deletions were restricted to stereochemically reasonable positions. A final alignment, including sequences from japanese encephalitis (strain
JaOArS982) and Dengue type 2 (strain PR-159), is shown in Figure 2 and is significantly different in several important respects from that given by Rey et al, 1995.
The most important differences, which are relevant to the subsequent insertion design are now described.
An insertion of two residues (122 and 123 in tbe) is introduced in tbe leading to a complete readjustment of the alignment up to the region of the glycosylation site between -strands Eo and Fo. On comparing the tbe and yellow fever (yf) sequences within the region 120 to 150 (tbe sequence numbering), the alteration leads to an increase in the number of sequence identities from 2 to 8. A similar improvement is observed for japanese encephalitis (je) and an increase from I to 10 identities occurs in the case of Dengue 2 (d2). Besides the clear improvement in sequence identity, the new alignment accommodates the two residue insertion (122 and 123 in tbe) in a surface loop (between p-strands d and e).
A deletion of one residue prior to strand f in yf and d2 is closed and transferred to the large deletion between -strands f and g. The deletion in this region of the alignment given in Figure 2 is thus 6 residues in length for both yf and d2, as it is in je, when compared to tbe.
The asparagine/aspartic acid rich segment of yf (residues 269 to 272) becomes an insertion between -strands k and I of domain II.
The sequence alignment was used to generate 10 models for the yf E protein dimer using satisfaction of spatial restraints derived from the tbe dimeric structure employing the program MODELLER (Sali A, Blundell, TL 1993, Comparative model building by satisfaction of spatial restraints..J Mol. Biol. 234,779-815). For each model a default coordinate randomization in cartesian space of 4 A was employed prior to model optimization using the Variable Target Function Method (Braun W, Go N
1985 Calculation of protein conformations by proton proton distance constraints-a new efficient algorithm JMol Biol 186, 611-626) and Simulated Annealing. Deliberate misalignment of residues surrounding insertions and deletions was used in order to relax the homology constraints of these residues, permiting the insertion/deletion while simultaneously maintaining acceptable stereochemistry.
The model which presented the lowest pseudo-energy, given by-ln (P), where P is the MODELLER molecular probability density function, also presented excellent overall stereochemistry, yielding for example a PROCHECK (Laskowski RA,
Macarthur MW, Moss DS, Thornton JM, 1993 Pro check - A Program To Check The
Stereochemical Quality Of Protein Structures, Journal OfAp , plied Crystallography 26 : 283-291) G-factor of-0. 1, equivalent to a crystal structure of better than 1.5 A resolution. The model was also evaluated using the method of Eisenberg (Eisenberg D,
Luthy R, Bowie JU, 1997, VERIFY3D : Assessment of protein models with threedimensional profiles Method Enzymol 277 : 396-404; Bowie JU, Luthy R, Eisenberg D
A, 1991, Method to Identify Protein Sequences that fold into a Known 3-Dimensional
Structure Science 253, 164-170 Luthy R, Bowie JU, Eisenberg D, 1992 Assessment Of
Protein Models With 3-Dimensional Profiles Nature 356,83-85), presenting a VERIFY3D score of 348, close to the expected value of 361 for a protein of 786 residues (in the dimer) and well above the acceptability threshold of 162. Furthermore
the normality of the model was assessed by atomic contact analysis using the WHA TIF overall quality score (Vriend G, 1990. What If-A Molecular Modeling And Drug Design Program J Mol Graphics 8 52-57 ; Vriend G, Sander C, 1993 Quality-Control Of Protein Models-Directional Atomic Contact Analysis JAppl Crystallogr 26 47-60) which gave a value of-0. 964, showing the model to be reliable.
The model for the yf E protein shows a slightly reduced contact area between subunits compared with tbe (1, 242A2 per monomer compared with 1, 503A2), partly due to the reduced size of the fg loop which makes intersubunit contacts via His208 in tbe.
There is a subsequent reduction in interdomain hydrophobic contacts as detected by
LIGPLOT (Wallace AC, Laskowski RA, Thornton JM, 1995. Ligplot-A Program To
Generate Schematic Diagrams of Protein Ligand Interactions Protein Eng 8 127-134).
These are compensated by the appearance of two potential intersubunit salt bridges
(between E201 and R243 and between R263 and E235) which appear in several of the ten models and which are absent, due to amino acid substitutions, in tbe. These salt bridges presumably aid in stabilizing the yf dimer. The contact made between the fusion peptide of the cd loop in domain II and the cavity between domains I and III of the opposite subunit is essentially retained in the yf E protein.
The model for the yf E protein together with the sequence alignment was used to select potential insertion sites for heterologous B and T cell epitopes. In both cases such an insertion site should 1) not disrupt or significantly destabilize the three-dimensional structure of the E protein; 2) not interfere with the formation of the E protein network within the viral envelope; 3) lie on the external surface of the virus such that it is accessible to anti-body. Although this criterion may not be strictly obligatory for T-cell epitopes it remains appropriate as sites on the internal surface may interfer with viral assembly. 4) The site should preferably present evidence that sequence length variation is permissible from the differences observed between different flaviviruses (ie. the site should show natural variance). 5) In the case of sites which present sequence length variation, preferably yf should present a smaller loop in such cases.
The first criterion limits insertion sites to loops and turns between elements of secondary structure. The second and third eliminate sites on the internal and lateral surfaces of the dimer and those that are buried. Of the remaining possible insertion sites, the following can be said. The loop between Do and a represents an interdomain connection and shows little structural variability. That between loops c and d represents the fusion peptide, is partially buried and highly conserved. That between d and e shows little structural variation and includes a 1/2-cystine residue which is structurally important. That between Eo and Fo includes the glycosylation site in tbe and is a potential insertion site as it shows great structural variability and is highly exposed. That between Go and Ho may be partially involved in lateral contacts, is a small-turn and shows little structural variation. That between f and g presents all of the desirable characteristics in that it is six residues shorter in yf, je and d2 compared with tbe and is externally exposed. That between k and 1 is a potential site as it shows an asparagine rich insertion in yf, which may accommodate asparagine-rich epitopic B-cell sequences as described below. That between B and Cx is a possible site but may form part of the
lateral surface. That between Dx and E shows structural variation and presents an asparagine-rich sequence in yf which may accommodate asparagine-rich epitopes.
From the above, the most promissing insertion site is that between p-strands f and g which form part of the five-stranded anti-parallel p-sheet of domain II. The large deletion of six residues in this loop in yf compared to tbe, leaves space at the dimer interface for a large insertion without creating steric hindrance. Besides the loop another promising insertion site is the EoFo as it shows great structural variability and is highly exposed. Although not wishing to be bound by any particular theory, it is postulated that the presence of one or more glycine residues immediately flanking the inserted epitope is advantageous in introducing conformational flexibility to the epitope in its subsequent presentation.
One alternative of the present invention to develop flavivirus in general as a vector for heterologous antigens is the insertion and expression of particular antigens, including epitopes, into sites structurally apart from areas known to interfere with the overall flavivirus E protein structure, specially into the loop or the EoFo loop of a given flavivirus E protein. The foreign inserted antigen, including epitope, may vary widely dependent on the immunogenic properties desired in the antigen. For example, the foreign inserted antigen may include antigens from protozoa such as malaria, from virus such as yellow fever, dengue, Japanese encephalitis, tick-borne encephalitis, fungi infections and others. Additionally, the maximum lenght of the antigen/epitope will depend on the fact that it would not compromise the structure and the function of the flavivirus envelope.
More particularly, one strategy described here is the insertion of malarial gene sequences into thefg loop ofYF17D E protein. While comparatively short sequences having only a few amino acid residues may be inserted, it is also contemplated that longer antigens/epitopes may be inserted. The maximum lenght and the nature of the antigen/epitope will depend on the fact that it would not compromise the structure and the function of the yellow fever virus envelope.
Malaria remains one of the most important vector-borne human diseases. The concept that vaccination may be a useful tool to control the disease is based mainly on
the fact that individuals continually exposed to infection by the parasitic protozoan eventually develop immunity to the disease.
The life cycle of the malaria parasite is complex, the several stages in humans are morphologically and antigenically distinct, and immunity is stage specific. It is only now becoming possible to define the full pattern of parasite gene expression in each stage.
In short, in the parasite life cycle sporozoites are delivered by the bite of the infected mosquito, find their way to the liver, and invade hepatocytes. Two proteins have been identified as implicated in the recognition and invasion of the hepatocytes,
CS (circumsporozoite) protein (Frevert, U., P. Sinnis, C. Cerami, W. Shreffler, B.
Takacs, and V. Nussenzweig. 1993. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J. Exp.
Med. 177: 1287-1298) and Thrombospondin-related anonymous protein or TRAP (Sultan, A. A. , V. Thathy, U. Frevert, K. J. Robson, A. Crisanti, V. Nussenzweig, R. S.
Nussenzweig, and R. M nard. 1997. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 90: 511-522). Antibodies to proteins on the parasite surface might conceivably neutralize sporozoites and prevent subsequent development of liver stages. In the hepatocyte the parasite differentiates and replicates sexually as a schizont to produce enormous amounts of merozoites that will initiate the infection of red blood cells. Antigens specific for the liver stage have been identified (Calle JM, Nardin EH, Clavijo P, Boudin C, Stuber D, Takacs B, Nussenzweig RS &
Cochrane AH. 1992. Recognition of different domains of the Plasmodium falciparum
CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers. J Immunol. 49 (8): 2695-701 ; Nardin, EH &
Nussenzweig, RS. 1993. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol.
1993 ; 11 : 687-727).
It has been proposed that these antigens together with those from the sporozoites are in part processed by the host cell and presented on the surface together with class I
MHC molecules. This presentation can lead to the recognition by cytotoxic T
lymphocytes and killing of the infected cells or stimulation of the T cells to produce cytokines can ultimately lead to the death of the intracellular parasite.
Merozoites surviving the pre-erythrocytic stages initiate the asexual blood stage infection, which is responsible for the disease. The parasite infects erythrocytes which do not express class I molecules and therefore cytotoxic T-lymphocytes are not important. Antibody binding to the surface of the merozoite probably plays a major role in immunity to asexual blood stages. Potentially these antibodies could neutralize parasites or lead to Fc-dependent mechanisms of parasite killing, e. g. , macrophages.
Complete protection against sporozoite challenge observed in irradiated P. berghei sporozoite-immunized mice and Pfalciparum sporozoite-immunized humans results from immune responses to antigens expressed by the parasite at the preerythrocytic stages of its life cycle (Nardin EH, Nussenzweig RS 1993. T cell responses to preerythrocytic stages of malaria: role in protection and vaccine development against preerythrocytic stages. Ann. Rev. Immunol. 11,687-).
Antibody, CD4+ and CD8+ T cells have been implicated in preerythrocytic immunity (Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V 1987. y-interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites Nature 330: 664-666; Rodrigues M, Li S, Murata K, Rodriguez D,
Rodriguez JR, Bacik I, Bennink JR, Yewdell JW, Garcia-Sastre A, Nussenzweig RS,
Esteban M, Palese P, Zavala F 1994. Influenza and vaccinia viruses expressing malaria
CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective response. Jlmmunol. 153,4636-4648).
There are 6 main preeythrocytic antigens in Pfalciparum parasites: the circunsporozoite protein (CS), thrombospondin related adhesion protein (TRAP), liverstage antigens 1 and 3 (LSA-1 and 3), Pis 16 and sporozoite threonine and asparaginerich protein. A number of epitopes identified on the diferent plasmodial proteins are being expressed in different systems towards immunogenicity studies (Munesinghe DY,
Clavijo P, Calle MC, Nardin EH, Nussenzweig RS 1991. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the
P. falciparum circunsporozoite protein. Eur. J. Immunol. 21,3015-3020 ; Rodrigues et al 1994; Shi YA, Hasnain SE, Sacci JB, Holloway BP, Fujioka H, Kumar N, Wohlhueter
R, Hoffman SL, Collins WE, Lal AA 1999. Immunogenicity and in vitro efficacy of a recombinant multistage Plasmodiumfalciparum candidate vaccine. Proc. Nail. Acad. Sci. USA 96,1615-1620 ; Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druilhe P, Hill AVS 2000. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3.
Infect. Immun. 68, 227-232).
Figure 3 shows a schematic representation of the CS protein of Plasmodium sp.
(Nardin e Nussenzweig, 1993) and the location of epitopes expressed by recombinant
YF 17D viruses of the present invention.
The CS protein contains an immunodominant B epitope located in its central area. This epitope consists of tandem repeats of species-specific amino acid sequences. In P. falciparum this epitope, asparagine-alanine-asparagine-proline, (NANP) has been detected in all isolates and thus represents an ideal target for vaccine development.
Initial clinical trials with synthetic or recombinant peptides administered with alum resulted in induction of rather modest levels of antibodies to sporozoites and only individuals with the highest levels of antibodies were protected against P. falciparum with delayed onset of parasitemia in others (Hoffman SL, Nussenzweig V, Sadoff JC, Nussenzweig RS 1991. Progress toward malaria preerythrocytic vaccines. Science 252: 520-521). Other studies in animals of passive transfer of monoclonal antibodies to the repeats of the CS protein also suggest that antibodies can provide protection against sporozoite infection. The problem that remains is to engineer vaccines that elicit levels of antibodies in humans with the appropriate specificity and affinity to destroy all of the sporozoites before they enter the hepatocytes. In this regard it is noteworthy that immunization of humans with a single dose YF 17D virus suffices to induce detectable levels of neutralizing antibodies to YF even after 40 years of the primary immunization (Monath, 1999) and that lends further support for the applicant of the present invention to use 17D virus to express relevant pathogens epitopes, especially the relevant malarial epitopes, towards the development of new live viral vaccines capable of protecting, being life-long against yellow fever and a second disease, for example malaria.
The liver stage of the parasite is also target for vaccine development because it offers additional antigens, and in contrast to the short-lived existence of sporozoites in the
bloodstream of the mammal host, human malarias develop in the liver for several days. The effector mechanisms against these intrahepatocytic forms are probably cytotoxic T cells that destroy the infected hepatocytes and y-interferon that inhibits parasite development.
Preerythrocytic immunity to Plasmodium is mediated in part by T lymphocytes acting against the liver stage parasite. These T cells must recognize parasite-derived peptides on infected host cells in the context of major histocompatibility complex antigens. T-cell-mediated immunity appears to target several parasite antigens expressed during the sporozoite and liver stages of the infection. A number of such
CTL epitopes, present on diferent proteins of the preerythrocytic stages, have been identified in humans living in malaria endemic areas and are restricted by a variety of
HLA class I molecules (Aidoo M, Udhayakumar V 2000 Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development.
Parasitol. Today 16,50-56).
Cytotoxic T cells, mostly CD8+, which require the class I antigen presentation pathway are primarily generated by intracellular microbial infections, and have been most thoroughly investigated in viral infections. Recombinant viruses expressing the desired foreign epitopes, are therefore a logical approach towards generating the cytotoxic T cells of the desired specificity.
Miyahira et al (Miyahira Y, Garcia-Sastre A, Rodriguez D, Rodriguez JR,
Murata K, Tsuji M, Palese P, Esteban M, Zavala F, Nussenzweig RS 1998.
Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. FroG. AM. Acad. Sci. USA 95,3954-3959) have studied in a mouse model the immunogenicity of a CTL epitope located on CS of
P. falciparum. The CTL epitope (DELDYENDIEKKICKMEKCS) was expressed in a bicistronic neuraminidase gene of the influenza D strain. Recombinant vaccinia included the whole CS gene containing both humoral and CTL epitopes. Immunization of mice with either flu or vaccinia elicited a modest CS-specific CD8+ T cell response detected by interferon y secretion of individual immune cells. Priming of mice with the recombinant flu virus and boosting with the vaccinia recombinant resulted in a striking enhancement of this response.
A vaccinia virus expressing several P falciparum antigens was developed and used in a clinical trial. While cellular immune responses were elicited in over 90% of the individuals antibody responses were generally poor. Of the 35 volunteers challenged, only one was completely protected, although there was a significant delay on the onset of parasitemia (parasitemia (Ockenhouse CF, Sun PF, Lanar DE, Wellde
BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR, et al.. 1998. Phase 1/IIa safety, immunogenicity, and efficacy trial ofNYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect
Dis. 177: 1664-1673).
Recombinant Sindbis virus expressing a minigene encoding the CD8+ T-cell epitope SYVPSAEQI of the CS protein of rodent malaria parasite P. yoelii when inoculated subcutaneously in mice induced a large epitope-specific CD8+ T-cell response. This immunization also protected mice against infection by sporozoites (Tsuji
M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, Nussenzweig RS,
Zavala F 1998. Recombinant Sindbis virus expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Viral. 72,6907-6910).
It has also been shown that mice immunized by a single dosis of a recombinant adenovirus expressing the CS protein of P. yoelii elicits a high degree of resistance to infection mediated primarily by CD8+ T cells (Rodrigues EG, Zavala F, Eichinger D,
Wilson JM, Tsuji M 1997. Single immunizing doses of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol. 158,1268-1274).
Because of the complexity of the parasite and its life cycle there is a consensus that a highly effective malaria vaccine would require a combination of key antigens and/or epitopes from different stages of the life cycle and that induction of both humoral and cellular immunity is required for optimal efficacy. Such a vaccine would also circumvent the problems with host genetic restriction and antigenic variability in the case of single antigen-based vaccines. So far, however, several attempts to attain
protective immunity with different antigens preparations from several stages have not produced convincing results.
The critical issues for the multivalent approach as with single antigen are the identification of antigens that will induce a (partially) protective response in all or most of the target population, the delivery of these antigens in a form that will stimulate the appropriate response and the delivery system must allow presentation of the antigens in a form that stimulates the immune system. The development described here which utilizes flaviviruses for the expression of defined pathogen antigens/epitopes should address the issues of presentation to the target population. Regarding the YF 17D virus, it is an extremely immunogenic virus, inducing high antibody seroconversion rates in vaccines of different genetic background.
The applicant of the present invention particularly explores the feasibility of using the YF 17D virus strain and substrains thereof, not only as a very effective proven yellow fever vaccine, but also as a vector for protective antigens, particularly protective epitopes. This will result in the development of a vaccine simultaneously effective against yellow fever and other diseases which may occur in the same geographical areas such as malaria, dengue, Japanese encephalitis, tick-borne encephalitis, fungi infections, etc.
The main goal was to establish a general approach to insert and express single defined antigens, including epitopes into sites structurally apart from areas known to interfere with the overall flavivirus E protein structure, specially into the loop or the
EoFo loop of the E protein of a given flavivirus, such as yellow fever, dengue, Japanese encephalitis, tick-borne encephalitis, that can be used as new live vaccine inducing a long lasting and protective immune response. More particularly, the present invention is related to a general approach to express single defined epitope on the loop of the E protein of a If 17D virus.
As used herein, the term"Flavivirus"means wild virus, attenuated virus and recombinant virus, including chimeric virus.
The genetic manipulation of the YF 17D genome was carried out by using the
YF infectious cDNA as originally developed by Rice et al (1989) which consists of two plasmids named pYF5'3'IV and pYFM5.2. The YF genome was splited in two plasmids
due to the lack of stability of some virus sequences in the high copy number plasmid vector, pBR322. However, in the case of dengue 2 virus, full length cDNA was steady cloned in the same plasmid (Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig
JT, Bhamarapravati N & Gubler DJ. 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK53. Virology. 230: 300-308). When cut by specific restriction enzymes (papal or Nsil and
AatII) specific restriction fragments are generated which upon ligation reconstitute the complete YF genome in the cDNA form. Restriction of this cDNA form with Xhol linearizes the cDNA and allows in vitro synthesis of capped RNA from the SP6 promoter sequence. Such RNA when transfected into cultured cells gives rise to infectious virus. The phenotype of this virus has been tested in monkeys (Marchevsky
RS, Mariano J, Ferreira VS, Almeida E, Cerqueira MJ, Carvalho R, Pissumo JW,
Travassos da Rosa APA, Simbes MC, Santos CND, Ferreira II, Muylaert IR, Mann GF,
Rice CM and Galler R. 1995. Phenotypic analysis of yellow fever virus derived from
complementary DNA. Am. J Trop. Med. Hyg. 52, 75-80) and these studies indicated the need for genetic modification of the cDNA as to make the resulting virus more attenuated. This has been carried out by Galler and Freire (US 6,171, 854) and resulted in new versions ofpYF5'3'IV and pYFM5.2, named Gl/2 and T3/27, respectively. The physical map and sequences of both plasmids are shown elesewhere and these plasmids have been deposited at ATCC (ATCC # 97771 and ATCC # 97772).
Having the genome split into two plasmids is convenient for insertion cloning purposes but not ideal for the recovery of the virus. So, in order to accomplish a higher specific infectivity of the transcripts the applicant developed a full-length cDNA clone for the YF genome. It was identified in the literature plasmid PACNRI 180 (Ruggli N;
Tratschin J-D. ; Mittelholzer C; Hofmann MA. 1996. Nucleotide sequence of classical
swine fever virus strain Alfort/187 and Transcription of infectious RNA from stably cloned full-length cDNA. J Viral. 70,3478-3487) which has a replication origin named PI 5A that allows only limited replication of the plasmid reducing the number of plasmid DNA molecules per bacterial cell. This plasmid system was used by the authors to stabilize the genome of the classical swine fever virus with a genome size
close to that of YF virus. This plasmid, PACNRI 180 was provided by Dr. JD Tratschin of Institute of Virology and Immunoprophylaxis, Switzerland.
Besides pACNRl 180, other vectors which provide the stabilization of the YF virus genome can be used to prepare the plasmids of the present invention. Specific examples include plasmids which have a replication origin that allows only limited replication of the plasmid reducing the number of plasmid DNA molecules per bacterial cells, i. e. vectors consisting of low copy number plasmids such as pBeloBACI 1 (Almazan F, Gonzalez JM, Penzes Z, Izeta A, Calvo E, Plana-Duran J, Enjuanes L.
2000 Engineering the largest RNA virus genome as an infectious bacterial artificial
chromosome. ProcNatlAcadSciUSA97 : 5516-5521). Another possibility is the use of high copy number plasmids such as pBR322.
The new version of PACNRI 180 was named pACNRI180Nde/Sal. It was obtained by removing most of the unique restriction sites of pACNRl 180 by digestion with NdeI/SalI, filling in the ends by treating with Klenow enzyme, ligating and transforming E. coli XL I-blue.
To generate pYF17D/14, fragments NotI (13, 059)-NsiI (11,158) and SaIl (3, 389)-XhoI (1951) from Gel/2 plasmid (described in detail in US 6,171, 854) were first ligated to NotI/XhoI-digested pACNR1180Nde/Sal. The resulting plasmid was named
NSK7 (map not shown) and used to clone the remaining of the YF cDNA contained in plasmid T3/27 (described in detail in US 6,171, 854) by digestion with NsiI (11, 158)
Sall (3,389), ligation of the appropriate fragments and transformation of the same bacterium. Restriction enzyme mapping confirmed the expected physical structure of a plasmid containing the complete YF cDNA. A total of 8 clones were analysed, virus was recovered from 5 out of 6 tested and complete nucleotide sequence determination confirmed the expected YF sequence. The plasmid contains 13449 base pairs and was named pYF17D/14 (Figure 4). pYF17D/14 contains an ampicillin resistance gene from position 13,196 to 545 and the pl 5A origin of replication (nts 763 to 1585) both derived from plasmid pACYC177 (Ruggli et al, 1996). Nucleotides 12,385 to 12,818 correspond to the SP6 promoter. The YF genome is transcribed in this plasmid from the opposite strand as the complete genome spans nucleotide 12,817 to 1951. All insertions at the fg loop of the
yellow fever virus E protein are made at the EcoRV site of YFE200 plasmid and from there incorporated into pYF17D/14 by exchanging fragments NsillNotl. Other representative sites are shown in Figure 4.
Plasmid Gl/2 contains the YF 5'terminal sequence (nt 1-2271) adjacent to the
SP6 phage polymerase promoter and 3'terminal sequence (nt 8276-10862) adjacent to the XhoI site used for production of run off transcripts. To allow the insertion of foreign sequences into the fg loop as defined by the analysis of the 3D structure of the E protein we have created by in vitro mutagenesis a restriction site (EcoRV) at nucleotide 1568. The creation of this site led to two amino acid changes in the E protein at positions E-199 and E-200 (E-+D, T-J, respectively).
It is important to emphasize that the creation of the restriction site of choice is dependent on the nucleotide sequence that makes up each loop and will vary according to the Flavivirus genome sequence to be used as vector. Therefore, the restriction site used for one Flavivirus EcoRV site is specific to the fg loop of yellow fever but (cortar?) may not be useful for insertion into the genome of other flavivirus. Those skilled in the art will identify suitable sites by using conventional nucleotide sequence analysis software for the design of other appropriate restriction sites.
It is noteworthy that amino acid 200 is a K in Asibi, T in all 17D viruses analyzed and I in E200. The fact that E200 is a position that is altered in all 17D viruses would suggest that particular alteration is important for the attenuation of 17D virus and alterations there might compromise that trait. However, the mutation introduced for the creation of the insertion site does not lead to reversion to the original amino acid and both are very distinct in character. Moreover, it is likely that attenuation of 17D is multifactorial, and not only related to the structural region as suggested the phenotype of chimeric 17D/JE-Nakayama in the mouse model of encephalitis (Chambers et al, 1999). In addition no major alterations in the E protein structure was apparent when modelling these amino acids changes into the predicted 3D model. Finally, the YF17D/GI/2-derived virus grew in tissue culture to the same levels and was as neurovirulent for mice as the parental 204/DD virus derived from G1/2/T3/27 cDNA.
In order to create the EcoRV site in the YF sequence we subcloned a NotI/Apal fragment of Gel/2 into the pAlter plasmid (Promega Inc) and performed the mutagenesis
as indicated by the manufacturer in the presence of mutagenizing synthetic oligonucleotide specifying the desired EcoRV site. Mutants bearing the site were identified by restriction enzyme analysis of plasmid DNA and the ApaI/NotI fragment contained in one of the clones was sequenced entirely to confirm the restriction site was the sole mutation in the YF sequence. Such fragment was cloned back into Gel/2 plasmid and the resulting plasmid was named pYFE200, the map of which is shown in
Figure 5.
This plasmid was derived from pYF5'3'IV originally described by Rice et al, 1989 as modified by Galler and Freire (patent number US 6,171, 854) and herein. It contains 6905 nucleotides and region 1-2271 corresponds to the 5'UTR, C, prM/M and
E genes. This region is fused through an EcoRI site at the E gene (2271) to another
EcoRI site in the NS5 gene (position 8276). At position 1568 in the E gene we created the EcoRV site which is used for epitope insertion into the E protein fg loop. This plasmid also consists of the NS5 gene from nucleotide 8276 to the last YF genome nucleotide (10,862) containing therefore part of the NS5 gene and the 3'UTR.
Nucleotides 5022 to 5879 correspond to the ampicillin-resistance gene and 6086 to 6206 to the origin of replication, both derived from pBR322 plasmid. Besides pBR322, other vectors known to specialists in the art may be used such as pBR325, BR327, pBR328, pUC7, pUC8, pUC9, pUC19, k phage, M13 phage, etc.. The location of relevant restriction enzyme sites is shown in Figure 5.
YFE200 plasmid has been deposited at ATCC under number PTA2856.
pYFE200 was used to produce templates together with T3/27 which allowed the recovery of YF virus that resembles YFiv5. 2/DD virus (US 6, 171, 854) in growth properties in Vero and CEF cells, plaque size, protein synthesis and neurovirulence for mice (data for E200 and the recombinants derived thereof are shown in the examples).
The template to be used for the regeneration of YF 17D virus is prepared by digesting the plasmid DNA (YFE200 and T3/27) with NsiI and Sail. After digestion with Xhol to linearize the ligated DNA, the template was used for in vitro transcription.
Virus has been recovered after RNA transfection of cultured animal cells.
The animal cell culture used herein may be any cell insofar as YF virus 17D strain can replicate. Specific examples include, Hela (derived from carcinoma of human
uterine cervix), CV-1 (derived from monkey kidney), BSC-1 (derived from monkey kidney), RK 13 (derived from rabbit kidney), L929 (derived from mouse connective tissue), CE (chicken embryo) cell, CEF (chicken embryo fibroblast), SW-13 (derived from human adrenocortical carcinoma), BHK-21 (baby hammster kidney), Vero (african green monkey kidney), LLC-MK2 (derived from Rhesus monkey kidney), etc.
In a preferred embodiment of the present invention, Vero cells are the preferred substrate in all production steps as the titers obtained in different growth curves, as well as the genetic stability gave better results. Primary cultures of chicken embryo fibroblasts (CEF) may be a second choice to be used as substrate in all production steps as these cells have been used for measles vaccine production for years with extensive experience in its preparation and quality controls; a number of Standard Operating
Practices (SOPs) is available and a patent application dealing with the production of YF vaccine in CEF cultures has been filled (EP 99915384.4)
Therefore, the flavivirus system described here, more particularly, the YF system, provides a powerful methodology for the development of unlimited formulations of recombinant viruses expressing different epitopes. It is anticipated that the appropriate formulation of several recombinant viruses should elicit the adequate immune response to cope with the different parasite stages.
The following examples are illustrative of the invention and represent preferred embodiments. Those skilled in the art may know, or be able to find using no more than routine experimentation, to employ other appropriate materials and techniques, such as the above mentioned vectors, culture cells and transfection methods.
Example 1: Structural analysis of the insertion of specific protein epitopes
Ten models were produced for the insertion SYVPSAEQI in the fg loop region using the alignment shown in Figure 6 in which the insertion is made between E 199 and
T200. The inserted residues will be refered to as 199A to 1991.
The pseudo-energies of the best five models were comparable to those of the native yf model. Their structures are variable as one skilled in the art would expect from an insertion of nine residues in length. The variation in structure of the loop leads to correlated variation in the neighbouring loop between-strands k and 1. The glutamine
sidechain of residue Glnl99H (ie the eigth residue of the inserted peptide) in several of the best models shows a conformation compatible with the formation of a hydrogen bond via its N to the carbonyl of Val244 of the opposite monomer in a similar fashion to that made by the No of His208 in tbe. One representative model had an overall Gfactor of 0.07, equivalent to a structure of < 1.0 A resolution and has good stereochemistry in the region of the insertion. The total Verify 3D score for the segment from 199 to 200 (including the nine inserted residues) is +3.69 (a mean value of 0.34 per residue) indicating that the residues of the loop have been built into favourable chemical environments. By comparison the mean value per residue for the equivalent loop in the crystal structure of tbe is only 0.28. The average contact area per monomer for this model is 1.460 A2, comparable to that observed in the crystal structure of tbe, as anticipated by the introduction of the insertion close to the proximal interface (Figure 7).
* During the construction of the insertion site two substitutions were made to the amino acid sequence: E199D and T200I. The consequence of such substitutions was analyzed with reference to the model. The substitution E199D is not expected to have serious consequences as it is conservative in nature, is observed in tbe and may lead to a salt-bridge with K123. There is also no significant change in the quality index for this residue as determined by WHATIF. The substitution T200I appears acceptable as the insertion leads to a rotation of the T200 sidechain in many of the ten models resulting in it being directed towards a hydrophobic pocket close to W203, the aliphatic region of
R263 and L245. The substitution also retains the ramification on C .
Using an identical approach to that described above the insertion DYENDIEKKI was introduced into the yf E protein. An identical alignment to that shown in Figure 6 was used in this case with the exception of the insertion sequence itself. Models were produced using an identical protocol to that described above for the SYVPSAEQI insertion and were of similar quality. Typically the models present PROCHECK Gfactors of-0. 1 (equivalent to crystal structures with a resolution between 1.0 and 1.5 A) and have around 90% of the residues within the most favourable regions of the
Ramachandran plot. Although the loop conformations obtained show considerable variation, several suggest the possible appearance of new inter-subunit interactions
which may affect dimer stability and/or influence the pH dependent dimer to trimer transition. Potential salt-bridges suggested by the models include those between Glul99C, Aspl99E and/or Glul99G (the third, fifth and seventh residues of the insertion respectively) with Arg243 (native yf numbering) of the opposite subunit as well as Lysl 99H with the carbonyl of Leu65 of the opposite subunit. The salt bridge seen in the native yf model between Arg263 of one monomer and Glu235 of the other, is retained. In none of the models did Lysl 99H form a hydrogen bond equivalent to that made by His208 to the opposite subunit in tbe, but a potential hydrogen bond to the carbonyl of Leu65 is possible. Lys 1991 may form a salt-bridge with Glul99 of the same subunit and such an interaction should be feasible even after the glutamic acid to aspartic acid substitution. On dimerization each subunit loses an average of 1,483 A of accessible surface area (based on one such model), comparable to that of tbe, principally due to the reinsertion of a large loop between-strands f and g.
Of note is the fact that neither of the two loop insertions described lead to steric clashes between the subunits, they preserve good steochemistry as well as (in the case of the best models) yielding reasonable chemical environments for the amino acid sidechains of the insertion. This is achieved without an exaggerated increase in the contact area between monomers suggesting that there is indeed no spatial restriction to the proposed insertions.
Compared with the loop observed experimentally in the crystal structure of the E protein from the tbe virus, the two insertions described above are three residues longer.
These additional residues are accommodated in most models by an additional protrusion of the structure on the external surface (although in one model a short stretch of a-helix is observed). This suggests that it may be possible to accommodate even larger peptides within this insertion site.
Ten models were generated for the insertion GG (NANP) 3GG and a protocol identical to that described in the previous two examples. Different from the previous two examples however is the fact that this insertion is a B-cell epitope, is considerably larger, includes a repeated tetrapeptide and is rich in proline residues. In this case in order that the B-cell epitope should be as exposed as possible (in order to be antibody accessible) and given adequate conformational freedom, as well as in facilitating its
insertion into the fg loop in the form of an Q loop (Leszczynski JF, Rose GD, 1986. Loops In Globular-Proteins-A Novel Category Of Secondary Structure Science 234, 849-855) two glycine residues (spacers) were added to both the N-and C-termini of the epitope, (NANP) 3. Due to the reduced size of the glycine sidechain and to its achiral
Ca atom, a greater region of Ramachandran space is accessible to its mainchain dihedral angles, (p and, increasing the chances of a sucessful insertion which does not prejudize the local structure in the region of the insert. This approach produced models which presented excellent stereochemistry (PROCHECK G-factors of the order of-0. 1, equivalent to crystal structures of resolution 1.0 to 1.5 A). The loop insertion itself is
also free of stereochemical strain. We surmise that this is the result of the N-and C terminal glycine spacers which serve to lift the loop free of the external surface of the protein. In several of the models one or more of these glycines adopt backbone conformations which would be prohibited for other amino acids. The remainder are generally in extended ( ) conformations. These factors appear to emphasize the importance of their inclusion.
Those skilled in the art will know that a reliable prediction of the structure of such a loop is beyond current theoretical approaches. There is therefore considerable spread in the resulting conformation in the ten models generated (Figure 8). This wide distribution of conformations (of approximately equal pseudo-energy) does not lead to significant alteration of the remainder of the structure, emphasizing that the loop has access to a large volume of space, as originally designed. This does not mean that the loop would necessarily be unstructured, merely that many possible structures are accessible to the loop, increasing the probability that that which is immunologically relevant may be adopted, even within the context of its insertion into the yf E protein.
Figure 9 illustrates better the volume considerations.
The (NANP) 3 sequence in the ten models has a mean relative accessible surface area (compared to its unfolded structure) of 63.7%. This compares with a mean value of 27.4% for the structure overall, demonstrating that the insertion has a very large relative accessibility, as intended. If the glycine spacers are eliminated this value for the (NANP) 3 sequence falls to 53.6%, demonstrating that the spacers have a role in increasing the exposure of the epitope. Examination of the models shows that
increasing the length of the glycine spacer beyond two residues would appear to bring no additional advantage in exposing the epitope but may represent an entropic cost for the structure which could lead to its destabilization. Two glycines appears the optimum to us.
It is a reasonable expectation that the envelope proteins of japanese encephalitis virus and Dengue 2 would accommodate the above described insertions equally well as yellow fever virus. The alignment of Figure 2 shows that a similar six-residue deletion
is present in all three viral envelope proteins compared to tbe. Models for the je and d2 E protein, produced using a similar protocol to that for yf, frequently show a-turn structure for the fg loop, stabilized by a mainchain hydrogen bond. A similar 5-turn is also observed in yf if the alignment restraints are relaxed around residues of the fg loop itself. The models for je show a potential intersubunit salt bridge between Lys201 with
Glu243 (je numbering) of the opposite subunit. This glutamic acid in yf interacts with
Arg263 which has been substituted by valine in je. Similar contacts to those of yf are also observed around the distal dimer interface site. A representative model for the je E protein has a PROCHECK G-factor of-0. 1,89. 9% of residues in the most favourable regions of the Ramachandran plot, good sterochemistry in the region of the fg loop (which adopts a type I -turn), a good WHATIF quality score for the fg loop (residues 203 to 212 yielding and average of 0.768) and buries a mean accessible surface area of 1,048 A per subunit on dimerization. Similar results are obtained for d2, in which the fg loop adopts either the type I or type II -turn conformation. From these data those skilled in the art will be able to apply the insertion strategy described above for yf to other flaviviruses such as je and d2.
The site which comprises the region of -strands f and g including the fg loop which form part of the five-stranded anti-parallel-sheet of domain II of the flavivirus envelope protein comprises the region of amino acid 196 to 215 with reference to the tick-borne encephalitis virus sequence described in figure 2. More particularly, the site is the loop area between -strands f and g which form part of the five-stranded antiparallel-sheet of domain II of the flavivirus envelope protein (amino acid 205 to 210 with reference to the tick-borne encephalitis virus sequence described in figure 2).
Additionally, the site which comprises the region of Eo and Fo strands including the EoFo loop which form part of the eight stranded ss-barrel of domain I of the flavivirus envelope protein comprises the region of amino acid 138 to 166 with reference to the tick-borne encephalitis virus sequence described in figure 2. More particularly, the site is the loop area between Eo and Fo strands which form part of the eight stranded ss-barrel of domain I (amino acid 146 to 160 with reference to the tick borne encephalitis virus sequence described in figure 2).
Example 2
a) Derivation of Plasmid pACNR1180Nde/Sal. pACNRl 180Nde/Sal, the new version of plasmid pACNR1180, is obtained by removing most of the unique restriction sites ofpACNR1180 by digestion with NdeI/SalI, filling in the ends by treating with Klenow enzyme, ligating and transforming
E. co/ ! XL 1-blue. This new version of PACNRI 180 was named pACNRl 180Nde/Sal. b) Derivation of Plasmid pYF17D/14 To generate pYF17D/14, fragments NotI (13, 059)-NsiI (11,158) and SaIl (3, 389)-XhoI (1951) from Gel/2 plasmid (described in detail in US 6,171, 854) were first ligated to NotI/XhoI-digested pACNR1180Nde/Sal. The resulting plasmid was named
NSK7 (map not shown) and used to clone the remaining of the YF cDNA contained in plasmid T3/27 (described in detail in US 6,171, 854) by digestion with Nsil (11, 158)- Sall (3,389), ligation of the appropriate fragments and transformation of the same bacterium. The plasmid contains 13449 base pairs and was named pYF17D/14 (Figure 4). pYF17D/14 contains an ampiciliin resistance gene from position 13,196 to 545 and the pl5A origin of replication (nts 763 to 1585) both derived from plasmid pACYC177 (Ruggli et al, 1996). Nucleotides 12,385 to 12,818 correspond to the SP6 promoter. The YF genome is transcribed in this plasmid from the opposite strand as the complete genome spans nucleotide 12,817 to 1951. All insertions at the fg loop of 17D virus E protein are made at the EcoRV site ofYFE200 plasmid and from there
incorporated into pYF17D/14 by exchanging fragments NsiI/NotI. Other representative sites are shown in Figure 4. c) Derivation of Plasmid YFE200.
In order to create the EcoRV site in the YF sequence we subcloned a Notl/Apal fragment of G 1/2 into the pAlter plasmid (Promega Inc) and performed the mutagenesis
as indicated by the manufacturer in the presence of mutagenizing synthetic oligonucleotide specifying the desired EcoRV site. Mutants bearing the site were identified by restriction enzyme analysis of plasmid DNA and the ApaI/NotI fragment contained in one of the clones was sequenced entirely to confirm the restriction site was the sole mutation in the YF sequence. Such fragment was cloned back into G1/2 plasmid and the resulting plasmid was named YFE200, the map of which is shown in
Figure 5. d) Preparation of Large amounts of plasmid DNA
To prepare plasmids DNAs from bacteria, glycerol stocks of the E. coli harboring each of the two YF plasmids, pYFE200 and pYF17D/14 must be available.
Luria Broth-50% glycerol media is used in the preparation of the stocks, which are stored at - 700C. Frozen aliquots of the pDNA are also available.
The bacteria are grown in 5 ml LB containing ampicillin (50 ug/ml) for
YFE200 and ampicillin (50 ug/ml) plus tetracyclin (15 ug/ml) overnight at 37 C for
NSK14-harboring bacteria. This is used to inoculate 1: 100 large volumes of LB (usually 100-200 ml). At OD6oo of 0.8, chloramphenicol is added to 250 jg/ml for the amplification of the plasmid DNA and incubated further overnight. The plasmid is extracted using the alkaline lysis method. The final DNA precipitate is ressuspended in
TE (Tris-EDTA buffer) and cesium chloride is added until a refraction index of 1.3890 is reached. The plasmid DNA is banded by ultracentrifugation for 24 hours. The banded
DNA is recovered by puncturing the tube, extracting with butanol and extensive dialysis.
The yields are usually 1 mg of pDNA/liter of culture for pYFE200 and 0.02 mg/liter for pYF17D/14.
pYFE200 was deposited on December 21, 2000 under accesion number PTA-2856 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Va.
20110-2209.
Example 3
Preparation of DNA template:
The template to be used for the regeneration of YF 17D virus is prepared by digesting the plasmid DNA (YFE200 and T3/27) with Nsil and Sail (Promega Inc. ) in the same buffer conditions, as recomended by the manufacturer. Ten u. g of each plasmid are digested with both enzymes (the amount required is calculated in terms of the number of pmol-hits present in each pDNA in order to achieve complete digestion in 2 hours). The digestion is checked by removing an aliquot (200 ng) and running it on 0.8% agarose/TAE gels. When the digestion is complete, the restriction enzymes are inactivated by heating.
Linearization of the DNA resulting from the ligation of both NSiI/SalI-digested plasmids is carried out by the use of Xhol, and is performed with buffer conditions according to the manufacturer (Promega). The resulting product is thereafter phenolchloroform extracted and ethanol precipitated. The precipitate is washed with 80% ethanol and resuspended in sterile RNase-free Tris-EDTA buffer. A template aliquot is taken for agarose gel analysis together with commercial markers for band sizing and quantitation. The template is stored at -200C until use for in vitro transcription.
Example 4
RNA transcription from cDNA template of the present invention:
Preparation of the DNA template from the full-length pYF 17D/14 clone for in vitro transcription is simpler as it requires less pDNA, usually 1-2 u. g which is digested with Xhol for linearization. Digestion, cleaning of the DNA and quality of the template are carried out as described above. Transcription is as described in US 6,171, 854.
RNA produced from Xhol-linearized pYF17D/14 DNA templates were homogeneous and mostly full-lenght in contrast to the two-plasmid system-derived RNA (data not shown).
Example 5 RNA transfection : Transfection of such RNA were carried out in a similar manner as described in
US 6,171, 854 (Galler and Freire). Transfection of such RNA gave rise to virus which was similar to YFiv5.2/DD in its plaque size, growth in Vero and CEF cells, neutralization by hyperimmune sera to YF and protein synthesis.
Example 6:
Construction of the recombinant YF17D/8 virus expressing a humoral B cell epitope.
For the expression of the (NANP) 3 humoral epitope of Pfalciparum (see Table 1 below) two surrounding glycines were added on each side as to compensate for the likely formation of-turn in the epitope given the presence of consecutive proline and asparagines and give the loop a more flexible structure. Therefore, the synthetic oligonucleotide insertion at the EcoRV site ofpYFE200 plasmid which corresponds to the amino acid sequence depicted in Table I gives rise to plasmid pYFE200/8. This plasmid was deposited on December 21,2000 under accesion number PTA-2857 with the American Type Culture Collection (ATCC), 10801 University Blvd. , Manassas, Va.
20110-2209.
Blunt-ended ligation of the synthetic oligonucleotide disrupts the EcoRV site and that was used to screen for plasmids bearing the insertion. EcoRV plasmids were sequenced around the insertion region to verify the orientation of the insert. Plasmids with correct insert orientation which therefore kept the required open reading frame were used for further sequence encompassing the whole structural region contained in this plasmid, more specifically, the area comprised between the NotI and Nsil sites.
The NotI/Nsil cDNA fragment of 1951 bp was ligated to the NsiI/MluI fragment of 1292 bp of the the T3 plasmid and the NotI/MluI backbone of 10,256 bp of the full lenght clone pYF17D/14. Resulting plasmids were first screened for size and thereafter for the production of infectious transcripts by lipid-mediated RNA transfection of cultured Vero cells as described (Galler and Freire, US 6,171, 854). The resulting virus
was named 17D/8. After transfection, YF 17D/8 had a titer (measured by plaquing on Vero cell monolayers) of about 4.0 logjoPFU/ml. After one-single passage in Vero cells viral stocks had a titer of 6. 1 logoPFU/ml. The presence of the insert in the viral genome was checked by sequencing the cDNA made to the virus present in the cell culture supernatant derived from the transfection.
Table 1: Amino acid sequence and specificity of (NANP) 3 humoral epitope for insertion into YF E protein
Sequence Antigen epitope source Clone EMD GGNANPNANPNANPGG IES CSP-B Pfalciparum 17D/8 Example 7 :
Epitope expression by the YF 17D/8 recombinant virus
To investigate the expression of the 16-amino acid epitope in the E protein of 17D/8 virus it was performed an indirect immunofluorescence assay using a monoclonal antibody directed to the (NANP) 3 repeat ( (MAb 2A10 ; Zavala F, Cochrane AH, Nardin
EH, Nussenzweig RS, Nussenzweig V 1983. Circunsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes.
JExp. Med 157,1947-1957) and a mouse polyclonal hyperimmune serum to YF 17D (ATCC). The IFA was made using glutaraldehyde-fixed VERO cells infected for 48 h with YF17D/14 virus or with recombinant virus YF 17D/8 carrying (NANP) 3 epitope at moi (multiplicity of infection) of 1. The samples were treated with twofold dilutions of
YF-Hiperimmune ascitic fluid (ATCC) and mouse IgG directed against the immunodominant B cell epitope NANP ofP. falciparum CS protein purified from 2Al 0 monoclonal antibody as described (Zavala et al, 1983, a gift of Dr. M. Rodrigues, Escola
Paulista de Medicina). Positive cells were evidenced by the binding of FITC
conjugated anti-mouse IgG. i c
Only Vero cells infected with 17D/8 virus were recognized by mab 2A 10 whereas the YF hyperimmune serum detected the YF antigens in both cases (see Figure 10).
Example 8:
Radiolabeling, Radioimmunoprecipitations and Polyacrilamide gel electrophoresis.
Additional evidence for correct plasmodial epitope expression on the surface of the 17D/8 virus was obtained by immunoprecipitation of metabolic labeled viral proteins. VERO cells were infected at a multiplicity of 1 PFU/cell. After 24 h incubation, the cells were labeled with [S] methionine for I h and lysed under nondenaturing conditions as described previously (Post et al, 1990). Cell extracts were immunoprecipitated by mouse policlonal hyperimmune ascitic fluid to YF (ATCC), two monoclonal antibodies against viral protein NS 1 (Schlesinger et al, 1983) and
P. falciparum repeat-specific monoclonal antibody (2AI0). Immunoprecipitates were fractionated with protein A-agarose and analysed by SDS-PAGE (Laemmli, 1970). For fluorographic detection, gels were treated with sodium salicylate and autoradiographed (Chamberlain, 1979). The results are shown in Figure 11. Immunoprecipitation profiles are obtained from protein extracts of mock-infected Vero cells (lanes 1,2, 3), 17D/14 (lanes 4, 5,6) or 17D/8 (lanes 7, 8,9) virus-infected monolayers. These different extracts were immunoprecipitated with a murine hyperimmune serum against yellow fever virus from ATCC (lanes 1,4, 7), (NANP) 3 repeat-specific monoclonal antibody or 2A10 (lanes 2,5, 8) and with two monoclonal antibodies direcetd against NS I (lanes 3,6, 9). Molecular weight markers are shown on the left side of the figure. The gel position of some of yellow virus proteins are indicated on the right side
Both parental and recombinant viruses produced the same protein profiles when the proteins were precipitated by the mouse hyperimmune serum and 2 monoclonal antibodies to YF 17D NS 1 protein (Figure 11 lanes lanes 4,6, 7 and 9). However, Mab 2.10 precipitated exclusively the E protein of the recombinant 17D/8 virus (lanes 5 and 8) consistent with the interpretation of correct expression and exposure on the surface of the epitope, as predicted by the structural analysis (Figures 11-13).
Example 9:
Viral neutralization assay by specific sera
A third set of experiments to show the correct E protein surface expression of the (NANP) 3 epitope was to examine viral neutralization by specific sera. We used a plaque reduction neutralization assay in Vero cells seeded at the density of 65, 000/cm2 on 96-well microplates as described elsewhere (Stefano et al 1999). Neutralizing antisera included an in-house standard rhesus monkey YF-immune serum (L13) and mab 2Al0. Plaque neutralization titers were calculated as the highest dilution of antibody reducing 50% of plaques of input virus, estimated by plating a mixture of virus serially diluted in fetal calf serum.
As observed in table 2 the anti YF L 13 serum neutralized both viruses with the same efficiency (approximately 1: 3, 500). Monoclonal antibody 2A10, however only neutralized the recombinant 17D/8 virus with an extremely high titer (1: 181, 000),
indicating the specificity of the neutralization. Table 2 : YF 17D virus neutralization by immune sera
serum YF 17 D YF 17D/8 L13 1 : 3, 715 1 : 3, 388 2 A 10 < 1 : 79 1 : 181, 970
In the case of the expression of the plasmodial (NANP) 3 epitope, the monoclonal antibody recognizes the linear sequence in itself as shown by the specificity of the neutralization. That suggests that the epitope is well exposed in the fg loop and its recognition is not hindered by its involvement in other viral epitope structures. It is also the first demonstration that a E protein linear epitope can be neutralizing for a flavivirus.
Fusion requires conformational changes that affect several neutralization epitopes, primarily within central domain I and domain II. These changes are apparently associated with a reorganization of the subunit interactions on the virion surface, with trimer contacts being favored in the low pH form, in contrast to dimer contacts in the
native form. Interference with these structural rearrangements by antibody binding represents one mechanism that may lead to virus neutralization (Monath and Heinz, 1996). Insertion of the plasmodial epitope in a loop of domain II also led to specific viral neutralization providing further evidence for the importance of this area in viral infectivity.
Example 10:
YF 17D/8 Recombinant virus attenuation
In order to demonstrate that the recombinant 17D/8 virus does not exceed its parent YF 17D virus in neuroinvasiveness and neurovirulence were carried out mouse tests.
In our analysis, groups of 16 3week-old Swiss mice were inoculated by the ic route with 3.0 logic PFU of the 17DD vaccine virus, a cDNA-derived 17D-LS3 virus and 17D/8 virus. Table 3 represents the average of two separate experiments. It is evident that the 17D/8 virus consistently kills less animals than the two other 17D viruses, 26 out of 32 for 17D/8 as opposed to 31 of 32 for the 17DD vaccine and LS3 viruses. The average survival time for animals inoculated with 17D/8 virus was also considerably longer as compared to the values obtained for the other two 17D viruses (12.5 vs 10.1 or 10.6, respectively).
Table 3: Mouse neurovirulence of YF17D viruses
virus IC dose % mortality Average survival (PFU) (dead/tested) time (days) control-0 (0/32) 3 17DD 103 96. 9 (31/32) 10. 6 17D-LS3 103 96. 9 (31/32) 10. 1 17D/8103 81. 3 (26/32) 12. 5
Swiss 3 week-old mice
YF 17D viruses were also examined for their capability of invading the central nervous system after peripheral (intra peritoneal, ip) inoculation into 2-5-7-9-day old Swiss mice. As shown in Table 4 below, the 17D/8 virus again behaved favourably as compared to the other 17D viruses used in being less neuroinvasive for 2 and 5-day old mice.
Epitope insertion at this site may affect the threshold of fusion-activating conformational change of this protein and it is conceivable that a slower rate of fusion may delay the extent of virus production and thereby lead to a milder infection of the host resulting in the somewhat more attenuated phenotype of the recombinant virus in the mouse model and lower extent of replication in cultured cells.
Table 4: Mouse Neuroinvasiveness of YF 17D Viruses
virus IP dose 2-day Average 5-day Average 7-day Average 9-day Average % mortality (n survival time % mortality (n survival time % mortality (n dead/survival time % mortality (n dead/survival time dead/n tested) dead/n tested) n tested) n tested) control-0 (0/12)-0 (0/16)-0 (0/7)-0 (0/16) 17DD 103 75 (9/12) 11. 1 87.5 (7/8) 11. 7 0 (0/16)-0 (0/14) 17D-LS3 103 78. 5 (11/14) 11.5 40 (4/10) 15. 5 21.4 (3/14) 17.3 5.5 (1/18) 18 17D/8 03 12.5 (1/8) 10.0 0(0/19) - 0(0/17) - 0(0/16)
Example 11 : Viral yields of YF 17D/8 in cultured cells.
In Vero cells, the YF 17D/8 virus produced tiny plaques (1. 10. 3 mm) when compared to virus YF5.2/DD (or YF 17D/14 virus 4. 200. 9 mm) and the small plaque 17D/Gl/5. 2-derived virus (1. 891. 05 mm). Figure 12 shows this data.
Viral growth curves were determined by infecting monolayers of VERO cells or primary cultures of chicken embryo fibroblasts (CEF) at m. o. i of 0.1 and 0.02 or at m. o. i of 0.1, 0.02 and 0.002, respectively. Cells were plated at density of 62,500 cell/cm2 and infected 24 h later. Samples of media were collected at 24h intervals postinfection. Viral yields were estimated by plaque titration on VERO cells.
Based on single step growth curves in Vero and CEF cells differences were also observed between 17D/8 and the control virus 17D/14. In CEF cultures, which are certified for human vaccine production, both viruses produced a peak titer at 48 hrs postinfection (Figure 13A). However maximal yields of 17D/8 reached 5x104 whereas the parental virus 17D/14 without the insert reached 106 PFU/ml. This difference of about 20 fold was kept until 96 hrs p. i. In Vero cells all viruses replicated better than in CEF cells but again the 17D/14-derived virus grew to 25 fold higher titers than 17D/8 (Figure 13B).
Example 12:
YF 17D vaccine virus production in certified cells
According to present manufacturing efficiency and the final viral titer per human dose, it needs an initial virus titer of at least 6.0 logioPFU/ml. It is obtained a titer of 6. 1 logioPFU/ml for 17D/8 in Vero cells. For vaccine manufacture,
addition of stabilizer to the virus bulk reduces titer by 0. 3 logioPFU/ml, filling and freeze-drying process reduces another 0. 6 log, OPFU/ml, a 0. 6 logloPFU/ml loss in thermostability is a rule, yielding a virus preparation ready for use as a vaccine with a final titer of 3. 9 logPFU/ml. This is the minimum dosis recommended by
the World Health Organization for YF vaccine in humans (WHO. 1995.
Requirements for Yellow Fever Vaccine).
Example 13:
YF 17D/8 Recombinant virus genetic stability
Therefore, the following experiments were carried out in order to characterize the genetic stability of the new virus (YF 17D/8) using cell cultures to propagate the virus:
With regard to insert stability:
The integrity of the insert must be assessed by sequencing of the RT/PCR products made on RNA of culture supernatant virus. The PCR product is sequenced directly to ensure all the amino acids are in place.
It is shown for YF 17DD/204 virus that to generate vaccine-productionsized secondary seed lots at least 3 passages are necessary starting from the cloned DNA plasmid (US 6,171, 854). Although the oligonucleotides encoding the epitopes were designed with codons more often utilized in the viral genome to avoid potential translation problems as well as instability of the inserted sequence, it is important to examine the maintenance of the insertion in the YF 17D virus genome.
For this purpose 5 series of separate passages ofYF17D/8 virus in Vero and CEF were performed with known MOI (0. 1-1. 0 PFU/cell). Then at selected (5th and 1 oath) passages the viral RNA was collected and subjected to nucleotide sequence determination (as RT-PCR products) at and around the insertion site in the E protein.
The results of these analyses in CEF and Vero cells are shown in Table 5.
The insert was present in both 5th and I Oth passages, suggesting its stability when the virus was passaged serially in Vero cells but not in CEF cells
Table 5 : Genetic stability of YF 17D8 virus insert upon serial passage in Vero and CEF cells.
Fifth passage insert Tenth passage insert CEF 17D/8 (5 a) * -17D/8 (lOa) 17D/8 (5 b)-17D/8 (lOb) Vero 17D/8 (5 c) + 17D/8 (10 c) + 17D/8 (5 d) + 17D/8 (10 d) + 17D/8 (5 e) + 17D/8 (10 e) + 17D/8 (5f) + 17D/8 (10 f) + 17D/8 (5 g) + 17D/8 (10 g) +
*The letters a and b represent two independent passages in CEF cells, whereas c, d, e, f, and g the five independent series of passages in Vero cells.
Plaque size analysis:
Aiming at the establishment of an in vitro marker for the recombinant virus we have studied the size of virus plaques formed on Vero cell monolayers.
One of the lineages from serial passages in CEF (a) or Vero cells (b) for which sequence data on the insert region were available was also analysed for its plaque size phenotype along the passaging process. Figure 14 displays the results of such analysis. It shows the plaque size of YF17D/8 is tiny compared to our large plaque YF 17DD/204 virus and the two small plaque 17D Gel/5. 2 and 17D/E200 viruses. All controls are viruses derived from cloned cDNA and have defined nucleotide sequence differences that are related to plaque size in Vero cells. In addition the plaque size displayed by both viruses is very homogeneous as expected from virus derived from cloned cDNA.
One of each lineages of the serial passages of YF 17D/8 virus in CEF (a) and Vero (b) cells were also analysed for their plaque size phenotypes along the passaging process (5th and loth passages, samples 5p and lOp, respectively). For the comparative plaque size analysis among viruses, the large plaque control, 17D/14 virus, the small plaque control, 17D/G1. 2 virus, and a 17D/8 virus,
representing second passage in Vero cells of the original virus recovered from RNA transfection, were used. Mean plaque diameters (mm) with the corresponding standards desviations were obtained at least from 10 different plaques of each virus.
In both cells the plaque size of serially passaged viruses tended to increase. As in Vero cell passaging there was no insert loss based on the sequencing data and plaque size phenotype in YF 17D viruses is dependent on one or more amino acid changes (AV Jabor and R Galler, unpublished) it is possible that other sequence changes took place outside the insertion area sequenced. We are presently analysing this possibility by sequencing the complete genome of YF 17D/8 virus but its expected sequence is shown comparatively to other viruses in Table 6.
Table 6: Comparison of YF infectious plasmid clone sequences.
NT/gene YFiv5.2a 17D/DDb YFiv5.2/DDc 17D/8 17D/1 17D/13 NT#AA 1140/E T C C T T T T#Val#C#Ala 1436,1437/E G, A A, G A, G G, A G, A G, A G, A#D#A,G#S 1946/E T C C T C C T#S#C#P 2219,2220/E A, C G, T G, T AC G, T G, T A, C#T#G, T= > V 2356/E T T C T T T 2602/NSl T T C T T T 2677/NS1 C C T C C C 2681/NS1 G G A G G G G#A#A#T 8656/NS5 A A C C A A 8808/NS5 A G G G G G A#N#G#S 9605/NS5 G A A A A A A#D#G#N 10454 G A A A A A 10722 G G A A G G
a Rice at al (1989) ; b Duarte dos Santos et al, 1995 ; C Galler and Freire, patent US 6, 171, 854
Example 14 : Immunogenicity in mice
The results described above suggested that the epitope is being presented in the correct conformation and is accessible to antibodies either in solubilized native E protein as well as on the virus surface. In this example it was looked further into the immunogenicity of the recombinant 17D/8 virus by examining its capability of eliciting antibodies. It was done by immunizing BALB/c mice separately with up to 3 doses (105 PFU/dose) by the intra peritoneal (IP) route given two weeks apart. Two weeks after the last dose blood was collected by intraorbital bleeding. Sera of mice were pooled and used to neutralize the homologous virus in 50% end-point plaque reduction neutralization tests.
Table 7 shows these results obtained from two independent experiments.
Intraperitoneal inoculation as the 3rd dose elicited an average antibody titer to the YF virus of 1: 1,079 as measured by PRNT 50.
Table 7 : Immunogenicity of YF 17D/8 virus in mice.
Immunizing Intra Peritoneal virus PRNT Average PRNT control 1 : 13- < 1 : 10 * < 1 : 13 17D/E200 1 : 166-1 : 195 1 : 181 17D/8 1 : 741-1 : 4171 : 1079
Reciprocal of the highest dilution of serum that resulted in 50% reduction of plaque numbers.
*These two different dilutions correspond to two set of independent experiments
Example 15 : Construction of others recombinant YF17D viruses expressing a cytotoxic T cell epitope
The recombinant viruses are constructed as described in Example 6 in order to express a cytotoxic T cell epitope. The recovery of the viruses from cDNA by transfection of Vero cells was carried out as in Example 6. The resulting viruses, YF 17D/1 and 17D/13 were further passaged twice in Vero cells for the generation of working stocks. The synthetic oligonucleotide insertion at the EcoRV site of YFE200 plasmid which corresponds to the amino acid sequence depicted in Table 8 below gives rise to plasmids pYFE200/l and pYFE200/13..
These plasmids were deposited on December 21,2000 under accesion number
PTA-2858 and PTA-2854, respectively, with the American Type Culture Collection (ATCC), 10801 University Blvd. , Manassas, Va.
Table 8 shows the predicted charge and isoelectric points for the epitopes alone, integrated into the fg loop and in the whole E protein context. As can be seen there is considerable variation of the net charge and the pI in each context, epitope alone, in the loop or in whole E contexts. Since the insertion region is involved in the pH-dependent conformatinal transition for fusion of the envelope to endosome membrane it is possible that this virus property could be influenced to different extents by the sequence in the epitope.
Preliminary data suggest that 17D/13 virus bearing the P. yoelii CTL epitope does not display the growth restrictions observed for the other viruses (17D/8 and 17D/l) in both CEF and Vero cells (Figure 13). Table 8 shows the amino acid sequence and specificity of selected epitopes for insertion into YF E protein.
Table 8: Amino acid sequence and specificity of selected epitopes for insertion into YF E protein.
YFfg loop EMD EMD EMD SYVPSAEQI IES DYENDIEKKI IES GGNANPNANPNANPGG IES Antigen epitope CSP-CTL CSP-B* CSP-CTL** Source P. falciparum P. falciparum P. yoelii Clone 17D/l 17D/8 17D/13 Charge/Peptide pf--2. 00/4.06 0.00/5. 97-1. 01/3.30 fg loop+epitope charge/pIa -2.00/3.69 -4.99/3.83 -4. 00/3. 49-3. 00/3. 58 YF E protein+epitope charge/pIa -7.4/5.83 -9. 40/5. 61-7. 40/5. 83-8. 40/5.71 5 *B, B cell **CTL, cytotoxic T cell epitope
Example 16 : Viral yields ofYF 17D/1 and 17D/13 in cultured cells.
The growth characteristics in Vero cells ofYF 17D/1 and 17D/13 comparatively to other 17D virus controls including te 17D/8 recombinant expressing the humoral epitope are analysed. This example is carried out following the protocol described in Example 11.
Figure 15 shows the comparative growth curves of the 17D/14, 17D/E200 and the malaria recombinant virus 17D/8, 17D/1 and 17D/13 in Vero cells at a moi of 0.1 pfu/ml. It is evident that 17D/1 and 17D/8 viruses grow to lower titers and more slowly than our 17D/14 virus control. On the other hand the 17D/E200 and 17D/13 viruses grew as efficiently as our control virus suggesting that the insertion of SYVPSAEQI epitope was not as deleterious in this aspect as the 2 others were. The same type of growth profile in Vero cells was observed with a different MOI (0.02) and in CEF cells with both MOIs (data not shown).
There are no significant differences in the overall charge and isoelectric point of the whole E protein containing these epitopes but differences can be observed at the level of the fg loop (see Table 8) containing or not the above epitopes, the hypothesis that the charge of the epitopes may influence pHdependent fusion and thereby lead to modified growth properties cannot be ruled out at this stage.
Example 17:
YF 17D/1 and YF 17D/13 recombinant virus genetic stability
With regard to insert stability:
As described in example 13 above for YF 17D/8 it was examined the stability of the insertion in the YF 1 7D virus genome by nucleotide sequence analysis at the insertion site on the RNA of viruses subjected to serial passages.
For this purpose each YF 17D/1 and 17D/13 viruses in Vero were performed with known MOI (0. 1-1. 0 PFU/cell). Then at selected (5th and 10th) passages the viral RNA was collected and subjected to nucleotide sequence determination (as
RT-PCR products) at and around the insertion site in the E protein.
The results of these analyses in CEF and Vero cells are shown in Table 9.
The insert was present in both 5th and 1 oath passages, suggesting its stability when the virus was passaged serially in Vero cells but not in CEF cells. Similarly to
YF17D/8 the inserted epitopes are stable throughout serial passaging of both viruses in Vero cells. These results, altogether, suggest the tolearbility of this site to the insertion of a wide variety of epitopes and endowing this system with an enormous potential for the creation of recombinant viruses expressing antigens of other pathogens in general.
Table 9 : Genetic stability of YF 17D recombinant viruses inserts upon serial passage in Vero cells
Fifth passage insert tenth passage insert 17D/l (5 h) + 17D/l (10 h) ND 17D/13 (5 i) + 17D/13 (10 i) + ND, not determined
Plaque size analysis : As shown in example 13 above the 17D/8 recombinant virus displayed a tiny plaque size phenotype as compared to our large plaque YF 17DD/204 (17D/14) virus and the two small plaque infectious cDNA-derived 17D Gel/5. 2 and 17D/E200 viruses. The plaque size phenotype for the new 17D/1 and 17D/13 recombinant viruses was compared to the viruses previously characterized (Figure 15). All viruses represent second passage in Vero cells of the original virus recovered from RNA transfection.
As expected from its growth profile in Vero cells (Figure 15) the 17D/13 virus displayed a plaque size similar to 17D/E200 and I7D/G1-5. 2, still small if compared to 17DD/204 (17D/14) but larger than the tiny plaques induced by 17D/1 and 17D/8 viruses (Figure 16).
Example 18:
YF 17D/1 and YF 17D/13 recombinant virus attenuation
Although mouse neurovirulence does not predict virulence or attenuation of YF viruses for humans, it was important to demonstrate that recombinant 17D/1 and 17D/13 viruses do not exceed its parent YF 17D virus in mouse neurovirulence. The YF 17D vaccine virus displays a degree of neurotropism for mice by killing all ages of mice after intracerebral inoculation and causes usually subclinical encephalitis in monkeys (Monath, 1999).
In the present analysis, groups of 16 3 week-old Swiss mice were inoculated by the ic route with 3.0 log) o PFU of the 17DD vaccine virus, 17Dl, 17D/8, 17D/13 and 17D/E200 viruses. The results shown in Table 10 are
representative of two separate experiments. Table 10 : Mouse neurovirulence of YF17D viruses
virus dose (PFU) % mortality Average survival time (days) (dead/tested) control-0 (1/32) 17DD 103 96. 9 (31/32) 9. 6 17D/1 103 81. 3 (26/32) 15. 6 17D/8 103 71. 9 (23/32) 11. 7 17D/13 103 53. 1 (17/32) 15. 3 17D/E200 103 93. 8 (30/32) 11. 0
Swiss 3 week-old mice
It is evident that the 17D/8 and 17D/13 viruses consistently kill less animals than the other 17D viruses, 96. 9% for 17DD and 81. 3% for 17D/1 and 93. 8% for 17D/E200. As observed previously the average survival time for animals inoculated with 17D/8 virus was also considerably longer as compared to
the values obtained for 17DD and 17D/E200 viruses (11. 7 vs 9. 6 or 11. 0, respectively). The I 7D/l and 17D/13 viruses killed mice at a much slower pace with ASTs of 15.4 and 15.1, respectively, but 17D/1 killed virtually all mice whereas 17D/13 was more attneuated and only killed 75%, similarly to 17D/8.
Epitope insertion at this site may affect the threshold of fusion-activated conformational change of the E protein and it is conceivable that a slower rate of fusion may delay the extent of virus production and thereby lead to a milder infection of the host resulting in the somewhat more attenuated phenotype of the recombinant virus in the mouse model and lower extent of replication in cultured cells.
The results shown here indicate that: inserts of different sizes and charges are tolerated and they are likely to influence the viral properties above. In no case, however, the recombinant virus became more neurovirulent for mice than its vaccine counterpart, further confirming the potential of using this site for the insertion of foreign epitopes and the development of new live attenuated 17D vaccines.
LIST SEQUENCING
I. a) Applicant: Funda ao Oswaldo Cruz I. b) Address: Av. Brasil, 4365, Castelo Mourisco, sala 05, Manguinhos-21045-900-Rio de
Janeiro-RJ
II) Invention: Use of Flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents.
III) Number of Sequences: 01 (one).
INFORMATION FOR SEQ ID NO: I I) Sequence characteristics: La) length: 10862 base pairs l. b) type: nucleic acid I. c) strandedness: single l. d) topology: linear I. e) molecule type: cDNA I. f) original source : individual isolate: Yfiv5.2/DD
I. g) sequence description: SEQ ID NO : 1:
1 AGTAAATCCT GTGTGCTAAT TGAGGTGCAT TGGTCTGCAA ATCGAGTTGC 51 TAGGCAATAA ACACATTTGG ATTAATTTTA ATCGTTCGTT GAGCGATTAG 101 CAGAGAACTG ACCAGAACAT GTCTGGTCGT AAAGCTCAGG GAAAAACCCT 151 GGGCGTCAAT ATGGTACGAC GAGGAGTTCG CTCCTTGTCA AACAAAATAA 201 AACAAAAAACAAAACAAATTGGAAACAGACCTGGACCTTCAAGAGGTGTT 251 CAAGGATTTA TCTTTTTCTT TTTGTTCAAC ATTTTGACTG GAAAAAAGAT 301 CACAGCCCAC CTAAAGAGGT TGTGGAAAAT GCTGGACCCA AGACAAGGCT 351 TGGCTGTTCT AAGGAAAGTC AAGAGAGTGG TGGCCAGTTT GATGAGAGGA 401 TTGTCCTCAA GGAAACGCCG TTCCCATGATGTTCTGACTG TGCAATTCCT 451 AATTTTGGGA ATGCTGTTGA TGACGGGTGG AGTGACCTTG GTGCGGAAAA 501 ACAGATGGTT GCTCCTAAAT GTGACATCTG AGGACCTCGG GAAAACATTC 551 TCTGTGGGCA CAGGCAACTG CACAACAAAC ATITTGGAAG CCAAGTACTG 601 GTGCCCAGAC TCAATGGAAT ACAACTGTCC CAATCTCAGT CCAAGAGAGG 651 AGCCAGATGA CATTGATTGC TGGTGCTATG GGGTGGAAAA CGTTAGAGTC 701 GCATATGGTA AGTGTGACTC AGCAGGCAGG TCTAGGAGGT CAAGAAGGGC 751 CATTGACTTG CCTACGCATG AAAACCATGG TTTGAAGACC CGGCAAGAAA 801 AATGGATGAC TGGAAGAATG GGTGAAAGGC AACTCCAAAA GATTGAGAGA 851 TGGTTCGTGA GGAACCCCTT TTTTGCAGTG ACGGCTCTGA CCATTGCCTA 901 CCTTGTGGGA AGCAACATGA CGCAACGAGT CGTGATTGCC CTACTGGTCT 951 TGGCTGTTGG TCCGGCCTAC TCAGCTCACT GCATTGGAAT TACTGACAGG 1001 GATTTCATTG AGGGGGTGCA TGGAGGAACT TGGGTTTCAG CTACCCTGGA 1051 GCAAGACAAG TGTGTCACTG TTATGGCCCC TGACAAGCCT TCATTGGACA 1101 TCTCACTAGA GACAGTAGCC ATTGATAGAC CTGCTGAGGC GAGGAAAGTG 1151 TGTTACAATG CAGTTCTCAC TCATGTGAAG ATTAATGACA AGTGCCCCAG 1201 CACTGGAGAG GCCCACCTAG CTGAAGAGAA CGAAGGGGAC AATGCGTGCA 1251 AGCGCACTTA TTCTGATAGA GGCTGGGGCA ATGGCTGTGG CCTATTTGGG 1301 AAAGGGAGCA TTGTGGCATG CGCCAAATTC ACTTGTGCCA AATCCATGAG
1351 TTTGTTTGAG GTTGATCAGA CCAAAATTCA GTATGTCATC AGAGCACAAT 1401 TGCATGTAGG GGCCAAGCAG GAAAATTGGA ATACCAGCAT TAAGACTCTC 1451 AAGTTTGATG CCCTGTCAGG CTCCCAGGAA GTCGAGTTCA TTGGGTATGG 1501 AAAAGCTACA CTGGAATGCC AGGTGCAAAC TGCGGTGGAC TTTGGTAACA 1551 GTTACATCGC TGAGATGGAA ACAGAGAGCT GGATAGTGGA CAGACAGTGG 1601 GCCCAGGACT TGACCCTGCC ATGGCAGAGT GGAAGTGGCG GGGTGTGGAG 1651 AGAGATGCAT CATCTTGTCG AATTTGAACC TCCGCATGCC GCCACTATCA 1701 GAGTACTGGC CCTGGGAAAC CAGGAAGGCT CCTTGAAAAC AGCTCTTACT 1751 GGCGCAATGA GGGTTACAAA GGACACAAAT GACAACAACC TTTACAAACT 1801 ACATGGTGGA CATGTTTCTT GCAGAGTGAA ATTGTCAGCT TTGACACTCA 1851 AGGGGACATC CTACAAAATA TGCACTGACA AAATGTTTTT TGTCAAGAAC 1901 CCAACTGACA CTGGCCATGG CACTGTTGTG ATGCAGGTGA AAGTGCCAAA 1951 AGGAGCCCCC TGCAGGATTC CAGTGATAGT AGCTGATGAT CTTACAGCGG 2001 CAATCAATAA AGGCATTTTG GTTACAGTTA ACCCCATCGC CTCAACCAAT 2051 GATGATGAAG TGCTGATTGA GGTGAACCCA CCTTTTGGAG ACAGCTACAT 2101 TATCGTTGGG AGAGGAGATT CACGTCTCAC TTACCAGTGG CACAAAGAGG 2151 GAAGCTCAAT AGGAAAGTTG TTCACTCAGA CCATGAAAGG CGTGGAACGC 2201 CTGGCCGTCA TGGGAGACGT CGCCTGGGAT TTCAGCTCCG CTGGAGGGTT 2251 CTTCACTTCG GTTGGGAAAG GAATTCATAC GGTGTTTGGC TCTGCCTTTC 2301 AGGGGCTATT TGGCGGCTTG AACTGGATAA CAAAGGTCAT CATGGGGGCG
2351 GTACTCATAT GGGTTGGCAT CAACACAAGA AACATGACAA TGTCCATGAG 2401 CATGATCTTG GTAGGAGTGA TCATGATGTT TTTGTCTCTA GGAGTTGGGG 2451 CGGATCAAGG ATGCGCCATC AACTTTGGCA AGAGAGAGCT CAAGTGCGGA 2501 GATGGTATCT TCATATTTAG AGACTCTGAT GACTGGCTGA ACAAGTACTC 2551 ATACTATCCA GAAGATCCTG TGAAGCTTGC ATCAATAGTG AAAGCCTCTT 2601 TCGAAGAAGG GAAGTGTGGC CTAAATTCAG TTGACTCCCT TGAGCATGAG 2651 ATGTGGAGAA GCAGGGCAGA TGAGATTAAT ACCATTTTTG AGGAAAACGA 2701 GGTGGACATT TCTGTTGTCG TGCAGGATCC AAAGAATGTT TACCAGAGAG 2751 GAACTCATCC ATTTTCCAGA ATTCGGGATG GTCTGCAGTA TGGTTGGAAG 2801 ACTTGGGGTA AGAACCTTGT GTTCTCCCCA GGGAGGAAGA ATGGAAGCTT 2851 CATCATAGAT GGAAAGTCCA GGAAAGAATG CCCGTTTTCA AACCGGGTCT 2901 GGAATTCTTT CCAGATAGAG GAGTTTGGGA CGGGAGTGTT CACCACACGC 2951 GTGTACATGG ACGCAGTCTT TGAATACACC ATAGACTGCG ATGGATCTAT 3001 CTTGGGTGCA GCGGTGAACG GAAAAAAGAG TGCCCATGGC TCTCCAACAT 3051 TTTGGATGGG AAGTCATGAA GTAAATGGGA CATGGATGAT CCACACCTTG 3101 GAGGCATTAG ATTACAAGGA GTGTGAGTGG CCACTGACAC ATACGATTGG 3151 AACATCAGTT GAAGAGAGTG AAATGTTCAT GCCGAGATCA ATCGGAGGCC 3201 CAGTTAGCTC TCACAATCAT ATCCCTGGAT ACAAGGTTCA GACGAACGGA 3251 CCTTGGATGC AGGTACCACT AGAAGTGAAG AGAGAAGCTT GCCCAGGGAC 3301 TAGCGTGATC ATTGATGGCA ACTGTGATGG ACGGGGAAAA TCAACCAGAT 3351 CCACCACGGA TAGCGGGAAA GTTATTCCTG AATGGTGTTG CCGCTCCTGC 3401 ACAATGCCGC CTGTGAGCTT CCATGGTAGT GATGGGTGTT GGTATCCCAT 3451 GGAAATTAGG CCAAGGAAAA CGCATGAAAG CCATCTGGTG CGCTCCTGGG 3501 TTACAGCTGG AGAAATACAT GCTGTCCCTT TTGGTTTGGT GAGCATGATG 3551 ATAGCAATGG AAGTGGTCCT AAGGAAAAGA CAGGGACCAA AGCAAATGTT 3601 GGTTGGAGGA GTAGTGCTCT TGGGAGCAAT GCTGGTCGGG CAAGTAACTC 3651 TCCTTGATTT GCTGAAACTC ACAGTGGCTG TGGGATTGCA TTTCCATGAG 3701 ATGAACAATG GAGGAGACGC CATGTATATG GCGTTGATTG CTGCCTTTTC 3751 AATCAGACCA GGGCTGCTCA TCGGCTTTGG GCTCAGGACC CTATGGAGCC 3801 CTCGGGAACG CCTTGTGCTG ACCCTAGGAG CAGCCATGGTGGAGATTGCC 3851 TTGGGTGGCG TGATGGGCGG CCTGTGGAAG TATCTAAATG CAGTTTCTCT 3901 CTGCATCCTG ACAATAAATG CTGTTGCTTC TAGGAAAGCA TCAAATACCA 3951 TCTTGCCCCT CATGGCTCTG TTGACACCTG TCACTATGGC TGAGGTGAGA 4001 CTTGCCGCAA TGTTCTTTTG TGCCGTGGTT ATCATAGGGG TCCTTCACCA 4051 GAATTTCAAG GACACCTCCA TGCAGAAGAC TATACCTCTG GTGGCCCTCA 4101 CACTCACATC TTACCTGGGC TTGACACAAC CTTTTTTGGG CCTGTGTGCA 4151 TTTCTGGCAA CCCGCATATTTGGGCGAAGG AGTATCCCAG TGAATGAGGC 4201 ACTCGCAGCA GCTGGTCTAG TGGGAGTGCT GGCAGGACTG GCTTTTCAGG 4251 AGATGGAGAA CTTCCTTGGT CCGATTGCAG TTGGAGGACT CCTGATGATG 4301 CTGGTTAGCG TGGCTGGGAG GGTGGATGGG CTAGAGCTCA AGAAGCTTGG 4351 TGAAGTTTCA TGGGAAGAGG AGGCGGAGAT CAGCGGGAGT TCCGCCCGCT 4401 ATGATGTGGC ACTCAGTGAA CAAGGGGAGT TCAAGCTGCT TTCTGAAGAG 4451 AAAGTGCCAT GGGACCAGGT TGTGATGACC TCGCTGGCCT TGGTTGGGGC 4501 TGCCCTCCAT CCATTTGCTC TTCTGCTGGT CCTTGCTGGG TGGCTGTTTC 4551 ATGTCAGGGG AGCTAGGAGA AGTGGGGATG TCTTGTGGGA TATTCCCACT 4601 CCTAAGATCA TCGAGGAATG TGAACATCTG GAGGATGGGA TTTATGGCAT 4651 ATTCCAGTCA ACCTTCTTGG GGGCCTCCCA GCGAGGAGTG GGAGTGGCAC
4701 AGGGAGGGGT GTTCCACACA ATGTGGCATG TCACAAGAGG AGCTTTCCTT 4751 GTCAGGAATG GCAAGAAGTT GATTCCATCT TGGGCTTCAGTAAAGGAAGA 4801 CCTTGTCGCC TATGGTGGCT CATGGAAGTT GGAAGGCAGA TGGGATGGAG 4851 AGGAAGAGGT CCAGTTGATC GCGGCTGTTC CAGGAAAGAA CGTGGTCAAC 4901 GTCCAGACAA AACCGAGCTT GTTCAAAGTG AGGAATGGGG GAGAAATCGG 4951 GGCTGTCGCT CTTGACTATC CGAGTGGCAC TTCAGGATCT CCTATTGTTA 5001 ACAGGAACGG AGAGGTGATT GGGCTGTACG GCAATGGCAT CCTTGTCGGT 5051 GACAACTCCT TCGTGTCCGC CATATCCCAG ACTGAGGTGA AGGAAGAAGG 5101 AAAGGAGGAG CTCCAAGAGA TCCCGACAAT GCTAAAGAAA GGAATGACAA 5151 CTGTCCTTGA TTTTCATCCT GGAGCTGGGA AGACAAGACG TTTCCTCCCA 5201 CAGATCTTGG CCGAGTGCGC ACGGAGACGC TTGCGCACTC TTGTGTTGGC 5251 CCCCACCAGG GTTGTTCTTT CTGAAATGAA GGAGGCTTTT CACGGCCTGG 5301 ACGTGAAATT CCACACACAG GCTTTTTCCG CTCACGGCAG CGGGAGAGAA 5351 GTCATTGATG CCATGTGCCA TGCCACCCTA ACTTACAGGA TGTTGGAACC 5401 AACTAGGGTT GTTAACTGGG AAGTGATCAT TATGGATGAA GCCCATTTTT 5451 TGGATCCAGC TAGCATAGCC GCTAGAGGTT GGGCAGCGCA CAGAGCTAGG 5501 GCAAATGAAA GTGCAACAAT CTTGATGACA GCCACACCGC CTGGGACTAG 5551 TGATGAATTT CCACATTCAA ATGGTGAAAT AGAAGATGTT CAAACGGACA 5601 TACCCAGTGA GCCCTGGAAC ACAGGGCATG ACTGGATCCT AGCTGACAAA 5651 AGGCCCACGG CATGGTTCCT TCCATCCATC AGAGCTGCAA ATGTCATGGC 5701 TGCCTCTTTG CGTAAGGCTG GAAAGAGTGT GGTGGTCCTG AACAGGAAAA 5751 CCTTTGAGAG AGAATACCCC ACGATAAAGC AGAAGAAACC TGACTTTATA 5801 TTGGCCACTG ACATAGCTGA AATGGGAGCC AACCTTTGCG TGGAGCGAGT 5851 GCTGGATTGC AGGACGGCTT TTAAGCCTGT GCTTGTGGAT GAAGGGAGGA 5901 AGGTGGCAAT AAAAGGGCCA CTTCGTATCT CCGCATCCTC TGCTGCTCAA 5951 AGGAGGGGGC GCATTGGGAG AAATCCCAAC AGAGATGGAG ACTCATACTA 6001 CTATTCTGAG CCTACAAGTG AAAATAATGC CCACCACGTC TGCTGGTTGG 6051 AGGCCTCAAT GCTCTTGGAC AACATGGAGG TGAGGGGTGG AATGGTCGCC 6101 CCACTCTATG GCGTTGAAGG AACTAAAACA CCAGTTTCCC CTGGTGAAAT 6151 GAGACTGAGG GATGACCAGA GGAAAGTCTT CAGAGAACTA GTGAGGAATT 6201 GTGACCTGCC CGTTTGGCTT TCGTGGCAAG TGGCCAAGGC TGGTTTGAAG 6251 ACGAATGATC GTAAGTGGTG TTTTGAAGGC CCTGAGGAAC ATGAGATCTT 6301 GAATGACAGC GGTGAAACAG TGAAGTGCAG GGCTCCTGGA GGAGCAAAGA 6351 AGCCTCTGCG CCCAAGGTGG TGTGATGAAA GGGTGTCATC TGACCAGAGT 6401 GCGCTGTCTG AATTTATTAA GTTTGCTGAA GGTAGGAGGG GAGCTGCTGA 6451 AGTGCTAGTT GTGCTGAGTG AACTCCCTGA TTTCCTGGCT AAAAAAGGTG 6501 GAGAGGCAAT GGATACCATC AGTGTGTTTC TCCACTCTGA GGAAGGCTCT 6551 AGGGCTTACC GCAATGCACT ATCAATGATG CCTGAGGCAA TGACAATAGT 6601 CATGCTGTTT ATACTGGCTG GACTACTGAC ATCGGGAATG GTCATCTTTT 6651 TCATGTCTCC CAAAGGCATC AGTAGAATGT CTATGGCGAT GGGCACAATG 6701 GCCGGCTGTG GATATCTCAT GTTCCTTGGA GGCGTCAAAC CCACTCACAT
6751 CTCCTATATC ATGCTCATAT TCTTTGTCCT GATGGTGGTT GTGATCCCCG 6801 AGCCAGGGCA ACAAAGGTCC ATCCAAGACA ACCAAGTGGC ATACCTCATT 6851 ATTGGCATCC TGACGCTGGT TTCAGCGGTG GCAGCCAACG AGCTAGGCAT 6901 GCTGGAGAAA ACCAAAGAGG ACCTCTTTGG GAAGAAGAAC TTAATTCCAT 6951 CTAGTGCTTC ACCCTGGAGT TGGCCGGATC TTGACCTGAA GCCAGGAGCT 7001 GCCTGGACAG TGTACGTTGG CATTGTTACA ATGCTCTCTC CAATGTTGCA 7051 CCACTGGATC AAAGTCGAAT ATGGCAACCT GTCTCTGTCT GGAATAGCCC 7101 AGTCAGCCTC AGTCCTTTCT TTCATGGACA AGGGGATACC ATTCATGAAG 7151 ATGAATATCT CGGTCATAAT GCTGCTGGTC AGTGGCTGGA ATTCAATAAC 7201 AGTGATGCCT CTGCTCTGTG GCATAGGGTG CGCCATGCTC CACTGGTCTC 7251 TCATTTTACC TGGAATCAAA GCGCAGCAGT CAAAGCTTGC ACAGAGAAGG 7301 GTGTTCCATG GCGTTGCCAA GAACCCTGTG GTTGATGGGA ATCCAACAGT 7351 TGACATTGAG GAAGCTCCTG AAATGCCTGC CCTTTATGAG AAGAAACTGG 7401 CTCTATATCT CCTTCTTGCT CTCAGCCTAG CTTCTGTTGC CATGTGCAGA 7451 ACGCCCTTTT CATTGGCTGA AGGCATTGTC CTAGCATCAG CTGCCTTAGG 7501 GCCGCTCATA GAGGGAAACA CCAGCCTTCT TTGGAATGGA CCCATGGCTG 7551 TCTCCATGAC AGGAGTCATG AGGGGGAATC ACTATGCTTT TGTGGGAGTC 7601 ATGTACAATC TATGGAAGAT GAAAACTGGA CGCCGGGGGA GCGCGAATGG 7651 AAAAACTTTG GGTGAAGTCT GGAAGAGGGA ACTGAATCTG TTGGACAAGC 7701 GACAGTTTGA GTTGTATAAA AGGACCGACA TTGTGGAGGT GGATCGTGAT 7751 ACGGCACGCA GGCATTTGGC CGAAGGGAAG GTGGACACCG GGGTGGCGGT 7801 CTCCAGGGGG ACCGCAAAGT TAAGGTGGTT CCATGAGCGT GGCTATGTCA 7851 AGCTGGAAGG TAGGGTGATT GACCTGGGGT GTGGCCGCGG AGGCTGGTGT 7901 TACTACGCTG CTGCGCAAAA GGAAGTGAGT GGGGTCAAAG GATTTACTCT 7951 TGGAAGAGAC GGCCATGAGA AACCCATGAA TGTGCAAAGT CTGGGATGGA 8001 ACATCATCAC CTTCAAGGAC AAAACTGATA TCCACCGCCT AGAACCAGTG 8051 AAATGTGACA CCCTTTTGTG TGACATTGGA GAGTCATCAT CGTCATCGGT 8101 CACAGAGGGG GAAAGGACCG TGAGAGTTCT TGATACTGTA GAAAAATGGC 8151 TGGCTTGTGG GGTTGACAAC TTCTGTGTGA AGGTGTTAGC TCCATACATG 8201 CCAGATGTTC TCGAGAAACT GGAATTGCTC CAAAGGAGGT TTGGCGGAAC 8251 AGTGATCAGG AACCCTCTCT CCAGGAATTC CACTCATGAA ATGTACTACG
8301 TGTCTGGAGC CCGCAGCAAT GTCACATTTA CTGTGAACCA AACATCCCGC 8351 CTCCTGATGA GGAGAATGAG GCGTCCAACT GGAAAAGTGA CCCTGGAGGC 8401 TGACGTCATC CTCCCAATTG GGACACGCAG TGTTGAGACA GACAAGGGAC 8451 CCCTGGACAA AGAGGCCATA GAAGAAAGGG TTGAGAGGAT AAAATCTGAG 8501 TACATGACCT CTTGGTTTTA TGACAATGAC AACCCCTACA GGACCTGGCA 8551 CTACTGTGGC TCCTATGTCA CAAAAACCTC AGGAAGTGCG GCGAGCATGG
8601 TAAATGGTGT TATTAAAATT CTGACATATC CATGGGACAG GATAGAGGAG 8651 GTCACCAGAA TGGCAATGAC TGACACAACC CCTTTTGGAC AGCAAAGAGT 8701 GTTTAAAGAA AAAGTTGACA CCAGAGCAAA GGATCCACCA GCGGGAACTA 8751 GGAAGATCAT GAAAGTTGTC AACAGGTGGC TGTTCCGCCA CCTGGCCAGA 8801 GAAAAGAGCC CCAGACTGTG CACAAAGGAA GAATTTATTG CAAAAGTCCG 8851 AAGTCATGCA GCCATTGGAG CTTACCTGGA AGAACAAGAA CAGTGGAAGA 8901 CTGCCAATGA GGCTGTCCAA GACCCAAAGT TCTGGGAACT GGTGGATGAA 8951 GAAAGGAAGC TGCACCAACA AGGCAGGTGT CGGACTTGTG TGTACAACAT
9001 GATGGGGAAA AGAGAGAAGA AGCTGTCAGA GTTTGGGAAA
GCAAAGGGAA
9051 GCCGTGCCAT ATGGTATATG TGGCTGGGAG CGCGGTATCT TGAGTTTGAG
9101 GCCCTGGGAT TCCTGAATGA GGACCATTGG GCTTCCAGGG AAAACTCAGG 9151 AGGAGGAGTG GAAGGCATTG GCTTACAATA CCTAGGATATGTGATCAGAG 9201 ACCTGGCTGC AATGGATGGT GGTGGATTCT ACGCGGATGA CACCGCTGGA
9251 TGGGACACGC GCATCACAGA GGCAGACCTT GATGATGAAC AGGAGATCTT 9301 GAACTACATG AGCCCACATC ACAAAAAACT GGCACAAGCA GTGATGGAAA
9351 TGACATACAA GAACAAAGTG GTGAAAGTGT TGAGACCAGC CCCAGGAGGG
9401 AAAGCCTACA TGGATGTCAT AAGTCGACGA GACCAGAGAG GATCCGGGCA
9451 GGTAGTGACT TATGCTCTGA ACACCATCAC CAACTTGAAA GTCCAATTGA
9501 TCAGAATGGC AGAAGCAGAG ATGGTGATAC ATCACCAACA TGTTCAAGAT
9551 TGTGATGAAT CAGTTCTGAC CAGGCTGGAG GCATGGCTCA CTGAGCACGG
9601 ATGTAACAGA CTGAAGAGGA TGGCGGTGAG TGGAGACGAC TGTGTGGTCC
9651 GGCCCATCGA TGACAGGTTC GGCCTGGCCC TGTCCCATCT CAACGCCATG 9701 TCCAAGGTTA GAAAGGACAT ATCTGAATGG CAGCCATCAA AAGGGTGGAA
9751 TGATTGGGAG AATGTGCCCT TCTGTTCCCA CCACTTCCAT GAACTACAGC
9801 TGAAGGATGG CAGGAGGATT GTGGTGCCTT GCCGAGAACA GGACGAGCTC
9851 ATTGGGAGAG GAAGGGTGTC TCCAGGAAAC GGCTGGATGA TCAAGGAAAC
9901 AGCTTGCCTC AGCAAAGCCT ATGCCAACAT GTGGTCACTG ATGTATTTTC
9951 ACAAAAGGGA CATGAGGCTA CTGTCATTGG CTGTTTCCTC AGCTGTTCCC
10001 ACCTCATGGG TTCCACAAGG ACGCACAACA TGGTCGATTC ATGGGAAAGG
10051 GGAGTGGATG ACCACGGAAG ACATGCTTGA GGTGTGGAAC AGAGTATGGA
10101 TAACCAACAA CCCACACATG CAGGACAAGA CAATGGTGAA
AAAATGGAGA
10151 GATGTCCCTT ATCTAACCAA GAGACAAGAC AAGCTGTGCG GATCACTGAT 10201 TGGAATGACC AATAGGGCCA CCTGGGCCTC CCACATCCAT TTAGTCATCC 10251 ATCGTATCCG AACGCTGATT GGACAGGAGA AATACACTGA CTACCTAACA 10301 GTCATGGACA GGTATTCTGT GGATGCTGAC CTGCAACTGG GTGAGCTTAT 10351 CTGAAACACC ATCTAACAGG AATAACCGGG ATACAAACCA CGGGTGGAGA 10401 ACCGGACTCC CCACAACCTG AAACCGGGAT ATAAACCACG GCTGGAGAAC 10451 CGGACTCCGC ACTTAAAATG AAACAGAAAC CGGGATAAAA ACTACGGATG 10501 GAGAACCGGA CTCCACACAT TGAGACAGAA GAAGTTGTCA GCCCAGAACC 10551 CCACACGAGT TTTGCCACTG CTAAGCTGTG AGGCAGTGCA GGCTGGGACA 10601 GCCGACCTCC AGGTTGCGAA AAACCTGGTT TCTGGGACCT CCCACCCCAG 10651 AGTAAAAAGA ACGGAGCCTC CGCTACCACC CTCCCACGTG GTGGTAGAAA 10701 GACGGGGTCT AGAGGTTAGA GAAGACCCTC CAGGGAACAA ATAGTGGGAC 10751 CATATTGACG CCAGGGAAAG ACCGGAGTGG TTCTCTGCTT TTCCTCCAGA 10801 GGTCTGTGAG CACAGTTTGC TCAAGAATAA GCAGACCTTT GGATGACAAA 10851 CACAAAACCACT
Claims (58)
1. A method for the production of Flavivirus as a vector for heterologous antigens comprising the introduction and expression of foreign gene sequences into insertion sites at the level of the envelope protein of any
Flavivirus, wherein the sites are structurally apart from areas known to interfere with the overall flavivirus E protein structure and comprising: (i) sites that lie on the external surface of the virus providing accessibility to antibody; (ii) not disrupt or significantly destablize the three-dimensional structure of the E protein; and (iii) not interfere with the formation of the E protein network within the viral envelope.
2. The method according to claim 1 wherein one site comprises the region of-strands f and g including the fg loop which form part of the fivestranded anti-parallel p-sheet of domain II of the flavivirus envelope protein.
3. The method according to claim 2 wherein the site is the loop area between ss-strands f and g which form part of the five-stranded anti-parallel ss- sheet of domain II of the flavivirus envelope protein.
4. The method according to claim 2 wherein the foreign sequence has been inserted in the region of amino acid 196 to 215 with reference to the tick borne encephalitis virus sequence described in figure 2.
5. The method according to claim 3 wherein the foreign sequence has been inserted in the region of amino acid 205 to 210 with reference to the tick borne encephalitis virus sequence described in figure 2.
6. The method according to claim 1 wherein another site comprises the region of Eo and Fo strands including the EoFo loop which form part of the eight stranded-barrel of domain 1.
7. The method according to claim 6 wherein the site is the loop area between Eo and Fo strands which form part of the eight stranded ss-barrel of domain 1.
8. The method according to claim 6 wherein the foreign sequence has been inserted in the region of amino acid 138 to 166 with reference to the tick borne encephalitis virus sequence described in figure 2
9. The method according to claim 7 wherein the foreign sequence has been inserted in the region of amino acid 146 to 160 with reference to the tick borne encephalitis virus sequence described in figure 2.
10. The method according to claim 1 wherein the Flavivirus is selected from the group consisting of any Flavivirus including yellow fever virus, tick borne encephalitis virus, dengue virus and japanese encephalitis virus.
11. The method according to claim 10 wherein the virus is a wild type, attenuated or recombinant virus.
12. The method according to claims 10 and 11 wherein the Flavivirus is a yellow fever virus.
13. The method according to claim 12 wherein the virus is a recombinant yellow fever virus.
14. The method according to claim 13 wherein the yellow fever virus is the YF 17D virus strain and substrains thereof.
15. The method according to claims I to 14 wherein the foreign epitope is a malarial gene sequence.
16. The method according to claim 15 wherein the malarial gene sequence is the (NANP) 3 humoral epitope.
17. The method according to claim 15 wherein the malarial gene sequence is the DYENDIEKKI cytotoxic T-lymphocytes (CTL) epitope.
18. The method according to claim 15 wherein the malarial gene sequence is the SYVPSAEQI cytotoxic T-lymphocytes (CTL) epitope.
19. The method according to claim 1 wherein one or more glycine residues is inserted in the region immediately upstream and downstream of the foreign epitope.
20. A DNA construct consisting essentially of a vector, a genetically stable Flavivirus genome and foreign gene sequences introduced in an insertion site according to any of claims 1 to 19.
21. The DNA construct according to claim 20 wherein the Flavivirus is selected from the group consisting of any Flavivirus including yellow fever virus, tick borne encephalitis virus, dengue virus and japanese encephalitis virus
22. The DNA construct according to claim 20 wherein the vector is selected from the group consisting of low copy number plasmids.
23. The DNA construct according to claim 21 wherein the vector is selected from the group consisting ofpACNRU180 and pBeloBAC 11.
24. The DNA construct according to claim 20 wherein the vector is selected from the group consisting of high copy number plasmids.
25. The DNA construct according to claim 20 wherein the genetically stable Flavivirus genome is derived from any YF 17D strain.
26. The DNA construct according to claim 25 wherein the genetically stable Flavivirus genome is the YF genome bearing the complete sequence set forth in SEQ ID NO : 1 or functionally equivalent sequences thereof.
27. The DNA construct according to claim 20 wherein the foreign gene sequence is derived from malaria, yellow fever, dengue, Japanese encephalitis, tick-borne encephalitis and fungi infections.
28. The DNA construct according to claim 27 wherein the foreign gene sequence is a malarial gene sequence.
29. The DNA construct according to claims 26 and 28 wherein the malarial gene sequence is the (NANP) 3 humoral epitope.
30. The DNA construct according to claim 28 wherein the malarial gene sequence is the DYENDIEKKI cytotoxic T-lymphocytes epitope.
31. The DNA construct according to claim 28 wherein the malarial gene sequence is the SYVPSAEQI cytotoxic T-lymphocytes epitope.
32. The DNA construct according to claim 29 which is plasmid pYF17D/8.
33. DNA construct having the structure of plasmid pYFE200.
34. DNA construct having the structure of plasmid pYFE200/1.
35. DNA construct having the structure of plasmid pYFE200/13.
36. DNA construct having the structure of plasmid pYFE200/8.
37. A Flavivirus as a vector for heterologous antigens comprising foreign gene sequences inserted at sites in the level of its envelope protein, wherein the sites are structurally apart from areas known to interfere with the overall flavivirus E protein structure.
38. The Flavivirus according to claim 37 wherein the foreign gene sequence is introduced in the region of ss-strands f and g including the fg loop which form part of the five-stranded anti-parallel p-sheet of domain II of the flavivirus envelope protein.
39. The Flavivirus according to claim 38 wherein the site is the loop area between ss-strands f and g which form part of the five-stranded anti-parallel p-sheet of domain II of the flavivirus envelope protein.
40. The Flavivirus according to claim 38 wherein the foreign sequence has been inserted in the region of amino acid 196 to 215 with reference to the tick borne encephalitis virus sequence described in figure 2.
41. The Flavivirus according to claim 39 wherein the foreign sequence has been inserted in the region of amino acid 205 to 210 with reference to the tick borne encephalitis virus sequence described in figure 2.
42. The Flavivirus according to claim 37 wherein another site comprises the region of Eo and Fo strands including the EoFo loop which form part of the eight stranded ss-barrel of domain 1.
43. The Flavivirus according to claim 42 wherein the site is the loop area between Eo and Fo strands which form part of the eight stranded ss-barrel of domain 1.
44. The Flavivirus according to claim 42wherein the foreign sequence has been inserted in the region of amino acid 138 to 166 with reference to the tick borne encephalitis virus sequence described in figure 2.
45. The Flavivirus according to claim 43 wherein the foreign sequence has been inserted in the region of amino acid 146 to 160 with reference to the tick borne encephalitis virus sequence described in figure 2.
46. The Flavivirus according to claim 37 wherein the Flavivirus is selected from the group consisting of any Flavivirus including yellow fever virus, tick borne encephalitis virus, dengue virus and japanese encephalitis virus.
47. The Flavivirus according to claim 46 wherein the virus is a wild type, attenuated or recombinant virus.
48. The Flavivirus according to claims 46 and 47 wherein the
Flavivirus is a yellow fever virus.
49. The Flavivirus according to claim 48 wherein the virus is a recombinant yellow fever virus.
50. The Flavivirus according to claim 49 wherein the yellow fever virus is the YF I 7D virus strain and substrains thereof.
51. The Flavivirus according to claims 37 to 50 wherein the foreign epitope is a malarial gene sequence.
52. A vaccine composition to immunize against flavivirus and other infectious agents consisting essentially of a virus according to claims 37 to 51.
53. The vaccine composition according to claim 52 wherein the flavivirus is a yellow fever virus and the other infectious agent is the causative agent of malaria.
54. The vaccine composition according to claim 53 wherein the malarial gene sequence is the (NANP) 3 humoral epitope.
55. The vaccine composition according to claim 53 wherein the malarial gene sequence is the DYENDIEKKI cytotoxic T-lymphocytes epitope.
56. The vaccine composition according to claim 53 wherein the malarial gene sequence is the SYVPSAEQI cytotoxic T-lymphocytes epitope.
57. The vaccine composition according to claims 37 to 51 comprising a sufficient amount of the virus and a pharmaceutically acceptable vehicle.
58. A Flavivirus as a vector for heterologous antigens wherein the
Flavivirus is obtainable according to any of claims I to 19.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0105877A GB2372991B (en) | 2001-03-09 | 2001-03-09 | Flavivirus expression vector |
PCT/BR2002/000036 WO2002072835A1 (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents |
BR0204470-6A BR0204470A (en) | 2001-03-09 | 2002-03-08 | Use of flaviviruses for the expression of protein epitopes and for the development of a novel live attenuated vaccine virus for immunization against flaviviruses and other infectious agents. |
CA002408214A CA2408214A1 (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents |
OA1200200375A OA12287A (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents. |
APAP/P/2002/002685A AP2002002685A0 (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents |
AU2002235678A AU2002235678B2 (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents |
EP02702182A EP1366170A1 (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents |
US10/275,707 US20030194801A1 (en) | 2001-03-09 | 2002-03-08 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents |
ZA200209371A ZA200209371B (en) | 2001-03-09 | 2002-11-18 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents. |
US11/205,117 US20060159704A1 (en) | 2001-03-09 | 2005-08-17 | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0105877A GB2372991B (en) | 2001-03-09 | 2001-03-09 | Flavivirus expression vector |
Publications (3)
Publication Number | Publication Date |
---|---|
GB0105877D0 GB0105877D0 (en) | 2001-04-25 |
GB2372991A true GB2372991A (en) | 2002-09-11 |
GB2372991B GB2372991B (en) | 2004-11-17 |
Family
ID=9910352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0105877A Expired - Fee Related GB2372991B (en) | 2001-03-09 | 2001-03-09 | Flavivirus expression vector |
Country Status (10)
Country | Link |
---|---|
US (2) | US20030194801A1 (en) |
EP (1) | EP1366170A1 (en) |
AP (1) | AP2002002685A0 (en) |
AU (1) | AU2002235678B2 (en) |
BR (1) | BR0204470A (en) |
CA (1) | CA2408214A1 (en) |
GB (1) | GB2372991B (en) |
OA (1) | OA12287A (en) |
WO (1) | WO2002072835A1 (en) |
ZA (1) | ZA200209371B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040390A1 (en) * | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | A recombinant vaccine using yellow fever virus as vector |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BR0210907A (en) * | 2001-06-01 | 2004-12-21 | Acambis Inc | Chimeric Flavivirus Vectors |
US20050002968A1 (en) * | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
NZ534159A (en) | 2002-01-15 | 2007-03-30 | Acambis Inc | Vaccines comprising flaviviruses with one or more hinge region mutations that reduce viscerotropism of the flaviviruses |
AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
JP4430543B2 (en) | 2002-10-09 | 2010-03-10 | シーアイディー カンパニー リミテッド | Japanese encephalitis virus full-length genomic RNA, JEV cDNA having infectivity to the JEV genomic RNA, and uses thereof |
US7416733B2 (en) | 2002-11-08 | 2008-08-26 | The Administrators Of The Tulane Educational Fund | Flavivirus fusion inhibitors |
JP4683926B2 (en) | 2002-11-15 | 2011-05-18 | サノフィ パスツール バイオロジクス カンパニー | West Nile virus vaccine |
AU2007297801A1 (en) * | 2006-07-14 | 2008-03-27 | Sanofi Pasteur Biologics Co. | Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
CA2668834C (en) | 2006-11-07 | 2016-10-11 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
US20080294361A1 (en) * | 2007-05-24 | 2008-11-27 | Popp Shane M | Intelligent execution system for the monitoring and execution of vaccine manufacturing |
WO2009024534A2 (en) * | 2007-08-17 | 2009-02-26 | Intercell Ag | Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses |
EP2589392B1 (en) | 2008-03-05 | 2016-11-30 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
EA201591888A1 (en) * | 2008-03-14 | 2016-05-31 | Санофи Пастер Байолоджикс Ко. | REPLICATION-DEFECT VACCINES AND VACCINE VECTORS AGAINST FLAVIVIRUSS |
EP2143440A1 (en) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus |
BRPI0916186B8 (en) | 2008-07-17 | 2021-05-25 | Medigen Inc | plasmid vector and its use, vaccine for yellow fever and for infectious RNA virus and homogeneous clonally purified live attenuated virus and its use |
US9198968B2 (en) * | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
BRPI0905645B8 (en) | 2009-10-27 | 2021-05-25 | Fundacao Oswaldo Cruz | DNA vaccine against yellow fever virus |
WO2013009884A1 (en) | 2011-07-12 | 2013-01-17 | The Government Of The United States America As Represented By The Secretary Of The Department Of Health And Human Services | Identification of a west nile virus cd4 t cell epitope and use thereof |
WO2013063248A1 (en) * | 2011-10-25 | 2013-05-02 | Florida Gulf Coast University | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
GB201307528D0 (en) * | 2013-04-26 | 2013-06-12 | Univ Leuven Kath | Bacterial artificial chromosomes |
BR102016018430A2 (en) * | 2016-08-10 | 2018-02-27 | Fundação Oswaldo Cruz | HETEROLOGICAL EXPRESSION CASSETTE, DNA CONSTRUCTION AND VACINAL COMPOSITION TO IMMUNIZE AGAINST FLAVIVIRUS AND / OR OTHER PATHOGENS. |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
EP4400174A2 (en) | 2017-09-01 | 2024-07-17 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031602A1 (en) * | 1995-04-01 | 1996-10-10 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
WO1999028487A1 (en) * | 1997-11-28 | 1999-06-10 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
ES2153223T3 (en) * | 1991-09-19 | 2001-02-16 | Us Health | CHIMERIC FLAVIVIRUS AND / OR RESTRICTED GROWTH FLAVIVIRUS. |
US5736148A (en) * | 1993-06-15 | 1998-04-07 | The United States Of America As Represented By The Secretary Of The Army | Infectious Japanese encephalitis virus cDNA clones that produce highly attenuated recombinant Japanese encephalitis virus, and vaccines thereof |
BRPI9701774B8 (en) * | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | mutant and infectious yellow fever virus cdna, DNA construct, recombinant yellow fever virus and human vaccine against yellow fever infections. |
EP1112372A1 (en) * | 1998-09-11 | 2001-07-04 | Genvec, Inc. | Alternatively targeted adenovirus |
-
2001
- 2001-03-09 GB GB0105877A patent/GB2372991B/en not_active Expired - Fee Related
-
2002
- 2002-03-08 EP EP02702182A patent/EP1366170A1/en not_active Withdrawn
- 2002-03-08 AU AU2002235678A patent/AU2002235678B2/en not_active Expired - Fee Related
- 2002-03-08 BR BR0204470-6A patent/BR0204470A/en not_active IP Right Cessation
- 2002-03-08 US US10/275,707 patent/US20030194801A1/en not_active Abandoned
- 2002-03-08 WO PCT/BR2002/000036 patent/WO2002072835A1/en not_active Application Discontinuation
- 2002-03-08 AP APAP/P/2002/002685A patent/AP2002002685A0/en unknown
- 2002-03-08 OA OA1200200375A patent/OA12287A/en unknown
- 2002-03-08 CA CA002408214A patent/CA2408214A1/en not_active Abandoned
- 2002-11-18 ZA ZA200209371A patent/ZA200209371B/en unknown
-
2005
- 2005-08-17 US US11/205,117 patent/US20060159704A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031602A1 (en) * | 1995-04-01 | 1996-10-10 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
WO1999028487A1 (en) * | 1997-11-28 | 1999-06-10 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
Non-Patent Citations (2)
Title |
---|
Brazilian J.Med.Biol.Res.,Vol.30,1997,Galler,R.et al.,"The yellow fever...",pp.157-168. * |
Virology,Vol.257,1999,Guirakhoo,F.et al.,"Immunogenicity, genetic stability...",pp.363-372. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040390A1 (en) * | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | A recombinant vaccine using yellow fever virus as vector |
Also Published As
Publication number | Publication date |
---|---|
GB0105877D0 (en) | 2001-04-25 |
WO2002072835A1 (en) | 2002-09-19 |
OA12287A (en) | 2006-05-12 |
AP2002002685A0 (en) | 2002-12-31 |
EP1366170A1 (en) | 2003-12-03 |
ZA200209371B (en) | 2004-02-18 |
GB2372991B (en) | 2004-11-17 |
CA2408214A1 (en) | 2002-09-19 |
US20060159704A1 (en) | 2006-07-20 |
US20030194801A1 (en) | 2003-10-16 |
AU2002235678B2 (en) | 2007-10-18 |
BR0204470A (en) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002235678B2 (en) | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents | |
AU2002235678A1 (en) | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents | |
JP5538729B2 (en) | Mock infectious flaviviruses and their use | |
AU2005295438B2 (en) | Vaccines against Japanese encephalitis virus and West Nile virus | |
Lai et al. | Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis | |
US8088391B2 (en) | West nile virus vaccine | |
CZ306499A3 (en) | Chimeric, vial, infectious, weakened virus, use thereof and nucleic acid molecule for treating flaviral infections | |
PT2278012E (en) | Immunogenic dengue 2 virus chimeras | |
WO2003092592A2 (en) | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | |
Bonaldo et al. | Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus | |
WO2017156511A1 (en) | Live attenuated zika virus vaccine | |
JP2016504315A (en) | Compositions, methods of administration and uses for trivalent dengue virus formulations | |
AU2003231185B2 (en) | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3 and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | |
JP2020534867A (en) | Mammal-specific growth-deficient arbovirus | |
MXPA99007949A (en) | Chimeric flavivirus vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20160309 |